| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Tiziana Life Sciences Ltd$1.23
-0.03 (-2.38%)
C 47Pipeline Score Fair Value Pharma · Clinical
Market Cap
175.90 M
EPS
-0.16
P/E Ratio
-
Value Trade
773.40 K
4.96 %
Week
19.35 %
1 Month
8.03 %
3 Month
-6.92 %
6 Month
-33.33 %
5 Year
-29.52 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
244.84 K
52 Week Range
1.14 - 2.60
% held by Insiders
51.02 %
% held by Institutions
2.44 %
Enterprise Value
172.35 M
Total Shares
118.85 M
Short %
2.11 %
Float Shares
74.04 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Tiziana Life Sciences Ltd
527Total events
2Upcoming
80Tier-1 (high impact)
2018 – 2026Coverage
Upcoming catalysts 2
Event history 525
Q3 2026
◆Topline ReadoutForalumabClinical Data
Topline data expected from Phase 2a trial of intranasal foralumab in na-SPMS
non-active Secondary Progressive Multiple Sclerosis (na-SPMS)source ↗
Jun 4, 2026
◆Oral PresentationPresentation
Tiziana Life Sciences to present at Jefferies Global Healthcare Conference
May 24, 2026
◆Poster PresentationForalumabPresentation
Late-breaking poster accepted for presentation at 7th World Parkinson Congress
Multiple System Atrophysource ↗
May 21, 2026
▲Enrollment CompleteForalumabTrial
Patient enrollment completed in Phase 2a trial of intranasal foralumab in na-SPMS
non-active Secondary Progressive Multiple Sclerosis (na-SPMS)source ↗
May 19, 2026
▲Full ResultsForalumabClinical Data
Updated clinical data from Expanded Access Program showing safety, EDSS stabilization, and fatigue improvement
non-active Secondary Progressive Multiple Sclerosissource ↗
May 14, 2026
▲Topline ReadoutForalumabClinical Data
Initial quantitative PET imaging results from first two MSA patients treated with intranasal foralumab show reduced brain inflammation
Multiple System Atrophysource ↗
May 14, 2026
▲Enrollment UpdateForalumabTrial
14 patients with na-SPMS dosed in open-label intermediate sized Expanded Access Program
Non-Active Secondary Progressive Multiple Sclerosissource ↗
May 14, 2026
●Trial InitiationForalumabTrial
Phase 2a trial in na-SPMS currently being studied
Non-Active Secondary Progressive Multiple Sclerosissource ↗
Apr 16, 2026
▲Preclinical PoCForalumabPreclinical
Positive preclinical data published in bioRxiv showing intranasal anti-CD3 antibody attenuates Long COVID neuroinflammation and improves cognitive function in mice
Long COVID neuroinflammationsource ↗
Apr 1, 2026
▲Preclinical PoCForalumabPreclinical
Nasal anti-CD3 improves cognition in aging model
age-related cognitive declinesource ↗
Feb 25, 2026
▲Poster PresentationForalumabPresentation
Late-breaking poster presented at Brigham and Women's Hospital showing biomarker data
non-active secondary progressive multiple sclerosis (na-SPMS) with progression independent of relapse activity (PIRA)source ↗
Drug Pipeline Intelligence
C47
Pipeline Score $288M
Pipeline ValueFair Value
Valuation Signal4
Drugs Scored1.6x
rNPV / MCap Top 69%
Micro Cap (rank 283 of 911)
Percentile RankTiziana Life Sciences Ltd carries a moderate pipeline score (47/100), with $3.1B risk-adjusted pipeline value, led by Foralumab in Secondary Progressive Multiple Sclerosis (Phase 2), across $59B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Foralumab Small molecule | Secondary Progressive Multiple Sclerosis | Phase 2 | NCT06292923 | 32% | $1.9B | ACTIVE NOT_RECRUITING | 54 | SLOW | C (59) | Oct 1, 2026 | ELEVATED_RISK | MEDIUM Jul 2, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
foralumab Fast Track | non-active secondary progressive multiple sclerosis | Phase 2a | 2026-05-28 | improvement or stability of disease seen within 6 months in all patients Read More | Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York Read More | |
foralumab Fast Track | non-active secondary progressive multiple sclerosis | Phase 2a | 2026-05-28 | improvement or stability of disease seen within 6 months in all patients Read More | Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York Read More | |
foralumab Fast Track | non-active secondary progressive multiple sclerosis | Phase 2a | 2026-05-28 | improvement or stability of disease seen within 6 months in all patients Read More | Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TLSA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TLSA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TLSATiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial
Tiziana Life Sciences has announced that the last patient has been dosed in its Phase 2a INFORM-MS trial, which evaluates intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis. The trial aims to assess safety and efficacy, with topline data expected in late Q3 or early Q4 of 2026. The results will be presented at an upcoming conference in Toronto.
Read more →TLSATiziana Life Sciences Announces Purchase of Shares by Executive Chairman
Tiziana Life Sciences announced that Executive Chairman Gabriele Cerrone has purchased 15,000 shares, increasing his total holdings to 44,772,230 shares. The company is advancing its lead candidate, intranasal foralumab, which is currently in clinical trials for non-active secondary progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody in development, showcasing a favorable safety profile.
Read more →TLSATiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
Tiziana Life Sciences will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026. CEO Ivor Elrifi and CFO Keeren Shah will discuss recent clinical updates, including the progress of their lead candidate, intranasal foralumab, which is currently being studied in patients with non-active secondary progressive multiple sclerosis. The presentation will include a Q&A session with investors.
Read more →TLSA▼ -9.3%on this news
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial BOSTON, MA
Tiziana Life Sciences has announced the completion of patient enrollment for its Phase 2 placebo-controlled clinical trial of intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). The INFORM-MS trial is significant as it marks the first placebo-controlled study of this monoclonal antibody, which targets neuroinflammation. The trial aims to measure the efficacy and safety of the treatment, with topline data expected in late Q3 2026. This milestone reflects both Tiziana’s efforts to address the limited treatment options available for na-SPMS and the company's commitment to advancing innovative therapies in neurodegenerative diseases.
Read more →TLSATiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
Tiziana Life Sciences has announced positive clinical data for intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis. The updated data indicate that the treatment is well tolerated and shows promising trends in stabilizing disability and improving fatigue. The findings support the potential of foralumab as a novel therapy for this patient population.
Read more →TLSATiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab
Tiziana Life Sciences has reported promising results from its Phase 2 clinical trial of intranasal foralumab in patients with Multiple System Atrophy (MSA). Initial PET imaging showed up to a 35% reduction in inflammatory activity in critical brain regions. This marks the third indication demonstrating the drug's potential to reduce neuroinflammation, building on previous findings in other neurodegenerative conditions.
Read more →TLSATiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab Foralumab is the first intranasal immune modulator in clinical trials for patients with Multiple System Atr
Tiziana Life Sciences has reported promising initial results from its Phase 2 clinical trial of intranasal foralumab in patients with Multiple System Atrophy (MSA). Two patients showed significant reductions in brain inflammation, with up to a 35% decrease in inflammatory activity in critical brain regions. This marks the third indication of effectiveness for intranasal foralumab, which has previously demonstrated beneficial effects in other neurological conditions. The company plans to continue evaluating the therapy to better understand its impact on neuroinflammation associated with MSA.
Read more →TLSATiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function
Tiziana Life Sciences announced positive preclinical data for its intranasal anti-CD3 antibody, foralumab, showing its ability to reduce neuroinflammation and enhance cognitive function in a Long COVID mouse model. The study, conducted by leading researchers, indicates that foralumab can effectively boost regulatory T cells in the brain and improve memory. These findings support its potential as a treatment for cognitive impairments associated with Long COVID.
Read more →TLSA▲ +12.2%on this newsshared move
Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress
Tiziana Life Sciences announced that a late-breaking poster on its Phase 2a study of intranasal foralumab for Multiple System Atrophy has been accepted for presentation at the 7th World Parkinson Congress. The study aims to evaluate the drug's potential to reduce neuroinflammation and microglial activation in MSA. The trial is currently enrolling participants and highlights a novel approach to treating this challenging condition.
Read more →TLSA▲ +12.2%on this newsshared move
Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7 th World Parkinson Congress BOSTON, MA
Tiziana Life Sciences has announced that a late-breaking poster on its Phase 2a study of intranasal foralumab in Multiple System Atrophy (MSA) has been accepted for presentation at the upcoming 7th World Parkinson Congress in May 2026. This poster will detail the trial's design and rationale, emphasizing foralumab's potential in targeting microglial activation associated with MSA. The trial aims to enroll up to 10 subjects, with primary endpoints assessing microglial activation and secondary endpoints evaluating brain atrophy, autonomic function, and quality of life. The CEO expressed excitement over the acceptance and the potential benefits for MSA patients.
Read more →TLSA▲ +6.8%on this news
Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging
Tiziana Life Sciences announced promising preclinical data for its nasal anti-CD3 monoclonal antibody, foralumab, indicating its potential to improve cognitive function associated with aging. The study revealed that nasal anti-CD3 reduces neuroinflammation and enhances neurogenesis in the hippocampus. Tiziana is advancing clinical trials for foralumab in various neurodegenerative conditions.
Read more →TLSATiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA
Tiziana Life Sciences announced positive biomarker data for its lead candidate, nasal foralumab, in treating non-active secondary progressive multiple sclerosis (na-SPMS). The data indicates that foralumab downregulates CSF inflammation and correlates with reduced microglial activation on PET scans. This supports the ongoing Phase 2 program and highlights the potential of foralumab in neuroinflammatory conditions.
Read more →TLSA▲ +8.2%on this news
Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab
Tiziana Life Sciences announced the peer-reviewed publication of its clinical study results for intranasal foralumab, a treatment for non-active secondary progressive multiple sclerosis (na-SPMS). The study, published in a leading neurology journal, highlights the drug's unique mechanism and positive outcomes. Tiziana is advancing intranasal foralumab in a Phase 2 trial, with results expected in 2026.
Read more →TLSA▼ -6%on this newsshared move
Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares
Tiziana Life Sciences has successfully closed an oversubscribed registered direct offering, raising $8.8 million by selling 7,040,000 ordinary shares at $1.25 each. The offering was conducted without underwriters and included participation from senior management. Proceeds will support the company's Phase 2 clinical trials for its lead candidate, intranasal foralumab.
Read more →TLSA▲ +15.9%on this newsshared move
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million
Tiziana Life Sciences announced a registered direct offering of approximately $17.6 million, pricing 6.4 million ordinary shares at $1.25 each. The offering will support the company's Phase 2 clinical trials for its lead candidate, intranasal foralumab. Key executives have increased their holdings, reflecting confidence in the company's future. The offering is expected to close on January 16, 2026.
Read more →TLSA▲ +15.9%on this newsshared move
Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares BOSTON, MA
Tiziana Life Sciences has announced the successful closing of an oversubscribed registered direct offering, raising $8.8 million through the sale of 7,040,000 ordinary shares. The offering was conducted without an underwriter, with significant participation from senior management including the CEO and Executive Chairman. Funds raised will be allocated towards completing Phase 2 clinical trials for intranasal foralumab, its lead candidate for treating non-active secondary progressive multiple sclerosis. The company aims to provide top line data readouts from these trials in the near future.
Read more →TLSATiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco
Tiziana Life Sciences will present its lead candidate, intranasal foralumab, at the 9th Annual Neuroscience Innovation Forum during J.P. Morgan Healthcare Conference Week. CEO Ivor Elrifi will discuss the company's progress in treating neurodegenerative conditions, particularly non-active secondary progressive multiple sclerosis. The event offers a platform for Tiziana to connect with investors and partners.
Read more →TLSATiziana Files Annual Safety Report for Intranasal Foralumab with FDA
Tiziana Life Sciences has submitted its seventh annual Development Safety Update Report (DSUR) for intranasal foralumab to the FDA, reporting no serious adverse events after 37.4 patient-years of exposure. The report emphasizes the safety and tolerability of foralumab in treating neuroinflammatory diseases. Tiziana's CEO noted the need for safe therapies following recent FDA decisions on competing treatments.
Read more →TLSATiziana Life Sciences Announces Acquisition of Shares by Executive Chairman
Tiziana Life Sciences announced that its Executive Chairman, Gabriele Cerrone, has acquired 97,687 common shares, increasing his total stake to 36.08% of the company. This move underscores his confidence in Tiziana's lead candidate, intranasal foralumab, which is currently being studied in clinical trials for non-active secondary progressive multiple sclerosis. The company aims to revolutionize immunotherapy with its unique delivery methods.
Read more →TLSATiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial
Tiziana Life Sciences has successfully dosed the first patient in its Phase 2 clinical trial for intranasal foralumab, targeting early Alzheimer's disease. The trial will assess the drug's efficacy both alone and in combination with existing anti-amyloid therapies. Preliminary data is expected in 2026, aiming to redefine treatment strategies for Alzheimer's by addressing chronic neuroinflammation.
Read more →TLSA▼ -6.7%on this newsshared move
Tiziana Life Sciences to Ring the Closing Bell at Nasdaq
Tiziana Life Sciences will ring the Nasdaq Closing Bell, celebrating its progress in immunomodulation therapies, particularly with its lead candidate, intranasal foralumab. This innovative approach aims to improve treatment efficacy for neurodegenerative diseases. The company has recently dosed its first patient in a Phase 2 Alzheimer's trial, highlighting its commitment to addressing unmet medical needs.
Read more →TLSA▲ +14%on this newsshared move
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
Tiziana Life Sciences' CEO, Ivor Elrifi, has purchased 163,400 shares of the company's stock, increasing his total holdings to 357,848 shares. The company is advancing its lead candidate, intranasal foralumab, which is currently in clinical trials for non-active secondary progressive multiple sclerosis. Early results indicate positive outcomes in patients treated with this unique immunomodulatory therapy.
Read more →TLSA▼ -10.7%on this newsshared move
Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering
Tiziana Life Sciences has announced the withdrawal of its proposed public offering of common shares, citing unfavorable market conditions. The company is focused on developing intranasal foralumab, a fully human anti-CD3 monoclonal antibody, which has shown promise in clinical studies. Despite the setback in fundraising, Tiziana continues to advance its innovative therapies.
Read more →TLSA▲ +6.3%on this newsshared move
Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial
Tiziana Life Sciences has initiated a Phase 2 clinical trial for intranasal foralumab, targeting early Alzheimer's disease. The trial will assess the drug's efficacy as both a standalone treatment and in combination with existing anti-amyloid therapies. The first patient is expected to be dosed next week, supported by new imaging evidence of persistent neuroinflammation in treated patients.
Read more →TLSATiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer's Trial First Patient Expected to be Dosed Next Week with Intranasal Foralumab PET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer's Patien
Tiziana Life Sciences has announced the commencement of patient dosing in its Phase 2 clinical trial for intranasal foralumab targeting Alzheimer's disease. The trial aims to assess the efficacy of foralumab alone and in conjunction with FDA-approved therapies like lecanemab. Recent PET imaging data indicates persistent neuroinflammation in patients despite previous amyloid treatment, highlighting the need for innovative solutions. As enrollment is underway, this trial may offer a new strategy for treating Alzheimer's by focusing on neuroinflammation.
Read more →TLSATiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company
Tiziana Life Sciences announced plans to spin out its IL-6 receptor monoclonal antibody, TZLS-501, into a separate publicly traded company. This move aims to enhance strategic focus and drive shareholder value, leveraging increased industry interest in IL-6 therapeutics. The transaction will require shareholder approval and is subject to listing criteria.
Read more →TLSA▲ +5.2%on this news
Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program
Tiziana Life Sciences announced that its Phase 2 clinical trial for intranasal foralumab in ALS patients has been accepted into the Healey ALS MyMatch Program. This trial aims to evaluate the drug's efficacy in a multi-site setting, leveraging innovative nasal immunology and advanced biomarkers. The study is supported by a grant from the ALS Association and aims to provide a non-invasive therapy for ALS.
Read more →TLSA▼ -7.3%on this news
Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference
Tiziana Life Sciences will present at the Jefferies London Healthcare Conference on November 19, 2025. CEO Ivor Elrifi and COO Keeren Shah will discuss the company's innovative pipeline, focusing on intranasal foralumab, a unique anti-CD3 monoclonal antibody. The presentation aims to showcase Tiziana's advancements in therapies for neurodegenerative diseases, enhancing its visibility in the biotech sector.
Read more →TLSATiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy
Tiziana Life Sciences will present its innovative immunomodulation therapy at BIO-Europe 2025 in Vienna. The company will highlight its lead candidate, intranasal foralumab, which aims to enhance treatment efficacy for neuroinflammatory diseases. Tiziana's participation emphasizes its commitment to advancing novel therapies and engaging with biopharma executives for strategic partnerships.
Read more →TLSATiziana Life Sciences Ltd ("Tiziana" or "the Company") Update and Interim Results for the Six Months Ended 30 June 2025 BOSTON, MA
Tiziana Life Sciences Ltd reported positive interim results for the six months ended June 30, 2025, highlighting advancements in their lead candidate, intranasal foralumab. The company is making notable progress in its clinical trials for neurodegenerative and autoimmune diseases, including multiple sclerosis and Alzheimer's disease. A new office in Boston aims to strengthen Tiziana's U.S. presence, benefiting from collaborations in a major biotech hub. However, the company also reported a comprehensive loss of $5.3 million, indicating ongoing financial challenges.
Read more →TLSATiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia
Tiziana Life Sciences has been invited to the Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia. This event, taking place on October 1-2, aims to connect biotech innovators with investors and industry leaders. Tiziana's CEO expressed the company's honor in participating, highlighting the opportunity to showcase their clinical pipeline and explore collaborations. The forum is aligned with Saudi Arabia's National Biotechnology Strategy.
Read more →TLSATiziana to Advance TZLS-501 – Its Fully Human IL-6R Monoclonal Antibody
Tiziana Life Sciences is advancing its fully human monoclonal antibody, TZLS-501, targeting IL-6 receptors. This decision comes amid increased industry interest in IL-6 therapies, particularly following Novartis' acquisition of Tourmaline Bio. TZLS-501 aims to reduce inflammation and cytokine levels, potentially benefiting various inflammatory diseases while Tiziana continues its focus on foralumab.
Read more →TLSA▲ +5.1%on this newsshared move
Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody
Tiziana Life Sciences is advancing its fully human anti-IL-6 receptor monoclonal antibody, TZLS-501, which targets both membrane-bound and soluble forms of IL-6R. This development comes amid increased industry interest in the IL-6 pathway, highlighted by Novartis' acquisition of Tourmaline Bio. Tiziana plans to pursue non-dilutive funding for TZLS-501 while continuing its lead program, intranasal foralumab.
Read more →TLSA▲ +11.9%on this newsshared move
Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress
Tiziana Life Sciences announced a poster presentation at the 41st ECTRIMS Congress, detailing the Phase 2a clinical trial of intranasal foralumab for non-active secondary progressive multiple sclerosis. This innovative therapy aims to improve treatment options for patients with limited alternatives. The presentation highlights the trial's design and objectives, showcasing Tiziana's commitment to advancing MS research.
Read more →TLSADepartment of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury
Tiziana Life Sciences has received a grant from the U.S. Department of Defense to study its intranasal anti-CD3 therapy for spinal cord injury. The three-year study will focus on acute SCI patients, while a separate award will investigate chronic cases. The therapy aims to improve neurological recovery and reduce inflammation, addressing a significant unmet medical need.
Read more →TLSATiziana Life Sciences Announces Purchase of Shares by Chairman
Tiziana Life Sciences announced that its Executive Chairman, Gabriele Cerrone, purchased 25,000 shares at $1.60 each, increasing his stake to 36.28% of the company. The company is advancing its lead candidate, intranasal foralumab, which is in clinical trials for non-active secondary progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody in development.
Read more →TLSA▲ +5.1%on this newsshared move
Tiziana Life Sciences Announces Purchase of Shares by Chairman BOSTON, MA
Tiziana Life Sciences announced that its Executive Chairman and Founder, Gabriele Cerrone, purchased 25,000 common shares at $1.60 each, increasing his total holdings to over 43 million shares. The company is focused on developing intranasal foralumab, an anti-CD3 monoclonal antibody, which is currently undergoing clinical trials for Non-Active Secondary Progressive Multiple Sclerosis. Early patient results from an open-label program show either improvement or stability of the disease. The nasal delivery method is being positioned as a novel approach to enhance treatment for neuroinflammatory diseases.
Read more →TLSA▼ -6.1%on this news· ran to -18% by day 3
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy
Tiziana Life Sciences has initiated its Phase 2a clinical trial for intranasal foralumab in patients with Multiple System Atrophy (MSA), a rare neurodegenerative disorder. The trial aims to evaluate the drug's ability to reduce neuroinflammation through a novel delivery method. This milestone is significant as there are currently no FDA-approved treatments for MSA, underscoring the need for new therapeutic options.
Read more →TLSA▲ +11.8%on this newsshared move
FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy
Tiziana Life Sciences has received FDA approval for its Phase 2a IND application to conduct a clinical trial using intranasal foralumab to treat patients with Multiple System Atrophy (MSA). This approval marks an important step in addressing an unmet medical need, as there are currently no FDA-approved therapies for this debilitating condition. The trial will evaluate the drug's effects on microglial activation, clinical outcomes, and safety over a six-month period. The approval highlights the potential of intranasal foralumab in targeting neuroinflammation, a key driver in MSA pathogenesis.
Read more →TLSATiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer’s Patient
Tiziana Life Sciences announced promising immunologic findings from a study of intranasal foralumab in a moderate Alzheimer's patient. The treatment demonstrated significant immune modulation, including reduced inflammation and enhanced phagocytosis of amyloid plaques. The patient continued therapy due to observed behavioral improvements, marking a potential breakthrough in Alzheimer's treatment.
Read more →TLSATiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient
Tiziana Life Sciences has reported promising immunologic findings from a treatment study of intranasal foralumab in a moderate Alzheimer's patient. Significant changes in immune cell profiles were observed, revealing a notable reduction in microglial inflammation and improved phagocytic ability in monocytes. These results suggest that foralumab may provide dual benefits by addressing both inflammation and amyloid accumulation in Alzheimer's Disease. The treatment was well tolerated with no side effects reported, and the patient has opted to continue therapy for an additional six months, marking a significant step in Alzheimer's research.
Read more →TLSA▲ +9.2%on this news
Tiziana Life Sciences to Present at the Bio International Convention
Tiziana Life Sciences will present its innovative intranasal foralumab at the upcoming Bio International Convention in Boston. The presentation, led by CEO Ivor Elrifi, will focus on the clinical findings related to this unique monoclonal antibody, which aims to enhance immune tolerance while minimizing systemic immune suppression. Currently, Tiziana is advancing with a Phase 2 trial for non-active Secondary Progressive Multiple Sclerosis and is preparing to initiate another trial for early Alzheimer's Disease, highlighting its commitment to addressing neuroinflammatory conditions.
Read more →TLSA▲ +9.2%on this news
Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center
Tiziana Life Sciences has announced the commencement of patient dosing in its Phase 2 clinical trial for intranasal foralumab at the Weill Cornell Medicine Multiple Sclerosis Center. This trial aims to evaluate the safety and efficacy of the treatment for non-active Secondary Progressive Multiple Sclerosis. With additional sites including reputable institutions like Yale and Johns Hopkins, Tiziana aims to address significant unmet medical needs in MS therapy. Intranasal foralumab represents a novel administration method and has shown promising results in earlier studies.
Read more →TLSA▲ +15.3%on this news
Interview Aired Nationwide Highlighting Intranasal Foralumab Treating Moderate Alzheimer’s Disease
Dr. Howard Weiner discussed the positive outcomes of intranasal foralumab in treating moderate Alzheimer's disease during an NPR interview. The first patient, Joe Walsh, showed a notable reduction in brain inflammation and improved social engagement. His wife, Karen, highlighted their transformative experience throughout the clinical trial.
Read more →TLSA▲ +15.3%on this newsshared move
Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease
Tiziana Life Sciences has announced advancements in the treatment of moderate Alzheimer's disease through their lead candidate, intranasal foralumab, highlighted in a recent interview. The treatment showed promising results in the first patient, Joe Walsh, who experienced notable improvements in engagement and social interaction after undergoing monoclonal antibody therapy via nasal administration. This development represents a significant step in Alzheimer's research, targeting brain inflammation, which is crucial in disease progression. Tiziana's novel approach to drug delivery may improve efficacy and safety over traditional intravenous methods.
Read more →TLSAJournal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer’s Disease
Tiziana Life Sciences announced the publication of a study in the Journal of Clinical Nuclear Medicine, demonstrating that intranasal foralumab significantly reduced microglial activation in a 78-year-old patient with moderate Alzheimer's disease. This case marks the first use of nasal foralumab in an Alzheimer's patient, showcasing promising results that could lead to further research and clinical trials. The findings suggest a potential new avenue for treating neuroinflammatory conditions.
Read more →TLSAJournal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease
A new study published in the Journal of Clinical Nuclear Medicine reveals promising results from Tiziana Life Sciences' intranasal foralumab in treating moderate Alzheimer's disease. This research highlights the significant reduction in neuroinflammation observed in a 78-year-old patient, marking a notable advancement in Alzheimer's treatment methodologies. The findings advocate for further investigation and controlled trials to validate the efficacy of nasal-foralumab as a viable therapy for this condition.
Read more →TLSATiziana Life Sciences Announces Purchase of Shares by Chairman New York
Tiziana Life Sciences Ltd. has announced that its Executive Chairman, Gabriele Cerrone, purchased 15,000 common shares, increasing his total holding to over 43 million shares, representing 37.02% of the company's capital. The company is advancing its lead candidate, intranasal foralumab, which has shown promise in treating non-active secondary progressive multiple sclerosis. With ongoing clinical trials, Tiziana's approach to immunotherapy may offer significant advantages over traditional methods.
Read more →TLSATiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer’s Patient Treated with Intranasal Foralumab
Tiziana Life Sciences announced encouraging results from a PET scan of a moderate Alzheimer's patient treated with intranasal foralumab, showing a significant reduction in microglia activation. This reduction indicates a potential therapeutic effect on neuroinflammation associated with Alzheimer's disease. The findings were presented at the 2025 AD/PD Conference, highlighting the need for innovative treatments in this area.
Read more →TLSATiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab
Tiziana Life Sciences has reported promising results from a PET scan showing a significant reduction in microglia activation in a patient with moderate Alzheimer's disease treated with intranasal foralumab. This notable decrease indicates the potential for foralumab to mitigate neuroinflammation associated with Alzheimer’s progression. The findings were presented by Dr. Howard Weiner at the 2025 AD/PD Conference and highlight the need for further studies. Currently, there are no approved therapies specifically for moderate Alzheimer’s, making these results particularly important.
Read more →TLSA▲ +23%on this newsshared move
Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis
Tiziana Life Sciences announced positive results from a study on nasal foralumab for treating non-active secondary progressive multiple sclerosis (na-SPMS). The study showed significant improvements in fatigue and stabilization of disability scores among patients. Additionally, the treatment demonstrated safety and reduced microglial activation, addressing a critical unmet need in MS management. A Phase 2 trial is set to further evaluate its efficacy.
Read more →TLSA▲ +23%on this newsshared move
Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis Meaningful Fatigue score reduction seen in study is a critically important quality of life
Tiziana Life Sciences announced positive results from a study on nasal foralumab for treating non-active secondary progressive multiple sclerosis (na-SPMS). The open-label study indicated that nasal foralumab is safe and can significantly improve quality of life by reducing microglial activation. The findings suggest that this novel therapy may address critical unmet needs in MS treatment, leading to a planned Phase 2 clinical trial aimed at further evaluating its efficacy. The encouraging results could result in a paradigm shift in MS treatment strategies.
Read more →TLSA▲ +12.9%on this news· ran to +24% by day 1
Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
Tiziana Life Sciences announced the commencement of dosing intranasal foralumab in its Phase 2 trial for non-active secondary progressive multiple sclerosis at the University of Massachusetts. This trial now includes four leading clinical sites, reflecting enthusiasm for the novel treatment approach. The study aims to assess the safety and efficacy of foralumab, a fully human anti-CD3 monoclonal antibody, with a completion date expected by the end of 2025. Following the blinded phase, all participants will have access to an open-label extension to evaluate long-term benefits.
Read more →TLSATiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial
Tiziana Life Sciences has announced that dosing has begun for its Phase 2 clinical trial of intranasal foralumab at Johns Hopkins University, a significant addition to the trial's existing sites. This randomized, double-blind, placebo-controlled trial aims to evaluate the safety, tolerability, and efficacy of foralumab in treating non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Early treatments in an open-label study indicated stabilization or improvement in patients' conditions. Tiziana is committed to developing novel therapies for neuroinflammatory diseases and looks forward to advancing this promising candidate.
Read more →TLSA▲ +13.9%on this news
Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial
Tiziana Life Sciences has commenced dosing new patients with intranasal foralumab in a Phase 2 clinical trial at Yale University, targeting non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This multicenter trial aims to evaluate the safety and effectiveness of foralumab, with participation from several prestigious medical centers. The study is expected to complete by the end of 2025 and includes a follow-up open-label extension phase. Intranasal foralumab represents a novel therapeutic approach, with prior early results indicating positive patient outcomes.
Read more →TLSATiziana Life Sciences to Present at the 37th Annual Roth Conference
Tiziana Life Sciences, a biotechnology company known for its immunomodulatory therapies, announced that CEO Ivor Elrifi will be presenting at the 37th Annual ROTH Conference, taking place from March 16-18, 2025. The company is developing intranasal foralumab, the only fully human anti-CD3 monoclonal antibody in clinical development. Foralumab has shown promising results in an Expanded Access program for patients with non-active secondary progressive multiple sclerosis. Additionally, Phase 2a trials are underway to further evaluate its efficacy and safety.
Read more →TLSATiziana Life Sciences to Present at the 37 th Annual Roth Conference
Tiziana Life Sciences announced that its CEO, Ivor Elrifi, will present at the 37th Annual ROTH Conference, scheduled for March 16-18, 2025, in Dana Point, California. The focus will be on intranasal foralumab, the company's lead immunomodulation therapy. This candidate has shown promise in an open-label study involving non-active secondary progressive multiple sclerosis patients. The FDA has allowed additional patient enrollment in the Expanded Access program, further underscoring the drug's potential in managing neuroinflammatory diseases.
Read more →TLSA▲ +6.1%on this newsshared move
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
Tiziana Life Sciences has regained compliance with Nasdaq's minimum bid price rule, allowing its securities to continue trading on the Nasdaq Capital Market. The company had been notified of non-compliance earlier this year but successfully met the requirements by maintaining the necessary share price for ten consecutive trading days. Concurrently, Tiziana's lead candidate, the intranasal anti-CD3 monoclonal antibody foralumab, is currently involved in clinical trials showing positive results for patients with non-active secondary progressive multiple sclerosis.
Read more →TLSATiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
Tiziana Life Sciences announced the filing of an Investigational New Drug application with the FDA to initiate a Phase 2 clinical trial for its therapeutic candidate, intranasal foralumab, aimed at treating Amyotrophic Lateral Sclerosis (ALS). This move reflects the company's commitment to developing innovative immunomodulation therapies for neurodegenerative diseases. Supported by a grant from the ALS Association, the trial will investigate the safety and efficacy of foralumab in ALS patients. The advancement represents a key step in addressing significant unmet medical needs within this critical therapeutic area.
Read more →TLSA▲ +15.3%on this news· ran to +32% by day 1shared move
Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury
Tiziana Life Sciences has published a study in Nature Neuroscience demonstrating that its nasal anti-CD3 monoclonal antibody, foralumab, significantly reduces neuroinflammation and improves recovery in traumatic brain injury (TBI) models. The therapy enhances the body's immune response, leading to better neurological outcomes. This breakthrough could offer a novel treatment approach for TBI patients.
Read more →TLSA▲ +15.3%on this news· ran to +32% by day 1shared move
Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti- CD3 Therapy in Traumatic Brain Injury Traumatic brain injury is a leading cause of deat
Tiziana Life Sciences announced the publication of a significant study in Nature Neuroscience, demonstrating that their nasal anti-CD3 monoclonal antibody, foralumab, effectively reduces neuroinflammation and enhances recovery in traumatic brain injury (TBI) models. The study showed correlation between the modulation of the neuroinflammatory response and improved neurological outcomes, including reduced anxiety and cognitive decline. This advancement highlights the potential of foralumab as a groundbreaking treatment for TBI, a condition lacking effective treatments currently. The study's findings also pave the way for further exploration of immune modulation in treating neuroinflammatory diseases.
Read more →TLSA▲ +6.1%on this news· ran to +43% by day 3shared move
Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter
Tiziana Life Sciences has announced that its preclinical study for intranasal foralumab, aimed at treating long COVID, is nearing completion. This innovative therapy intends to address the neurological and psychiatric symptoms associated with long COVID by reducing microglial activation, which contributes to brain inflammation. The company's previous clinical studies demonstrated that intranasal foralumab was well-tolerated and effective for reducing lung inflammation, enhancing hopes for its use in long COVID treatment. Tiziana's approach reflects a growing interest in targeting neuroinflammatory conditions post-COVID-19 infection.
Read more →TLSA▼ -8.9%on this newsshared move
Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood
Tiziana Life Sciences has entered a product development services agreement with Renaissance Lakewood to enhance the formulation and manufacturing process for its lead candidate, intranasal foralumab. The collaboration is expected to support the optimization of this novel immunotherapy aimed at neuroinflammatory and neurodegenerative diseases. Recent studies have shown favorable outcomes in clinical trials, contributing to a positive outlook for the drug's advancement. This agreement is a pivotal step towards Tiziana's mission for potential commercialization of intranasal foralumab.
Read more →TLSA▲ +11.1%on this newsshared move
Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program
Tiziana Life Sciences has announced the dosing of four additional patients in its Expanded Access Program for non-active secondary progressive multiple sclerosis (na-SPMS), bringing the total to 14. Notably, the first 10 patients reported either stability or improvement in their condition within six months. This program allows access to the company's investigational therapy, intranasal foralumab, for patients who do not qualify for the ongoing Phase 2a trial. Tiziana's management expressed commitment to addressing unmet medical needs in the na-SPMS patient population.
Read more →TLSATiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease
Tiziana Life Sciences has announced that its investigational drug, intranasal foralumab, was featured in a TV interview showcasing the first patient dosed under the expanded access program for moderate Alzheimer's disease. The segment presented the patient's experiences and the potential of foralumab to target inflammation linked to neurodegeneration. Experts, including Dr. Howard Weiner, emphasize the innovative delivery method and the drug's promise in potentially improving cognitive function for Alzheimer's patients. The company continues to explore broader applications for this therapy in treating neurodegenerative diseases.
Read more →TLSA▲ +11.1%on this news
Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3
Tiziana Life Sciences has reported positive results from studies using nasal anti-CD3 monoclonal antibody for treating spinal cord injuries. The preclinical models demonstrated notable advancements in motor functions following treatment, suggesting a potential breakthrough in therapy for this devastating condition. The company aims to extend its innovative nasal foralumab technology, already in trial for multiple sclerosis, to spinal cord injury treatment, highlighting its commitment to address significant medical challenges.
Read more →TLSA▲ +11.1%on this news
Tiziana Life Sciences not to engage in capital raising activities for the immediate future
Tiziana Life Sciences, a biotechnology firm focused on immunomodulation therapies, announced that it will not engage in capital-raising activities in the immediate future. This decision follows their recent discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis who were treated with their lead candidate, intranasal foralumab. The company remains dedicated to advancing clinical trials and regulatory processes to enhance shareholder value.
Read more →TLSA▲ +8.5%on this news· ran to +21% by day 1shared move
Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab
Tiziana Life Sciences announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with their intranasal product, foralumab. The study identified gene expression changes that occur following treatment and indicated mechanisms of immune modulation. This breakthrough could enhance personalized treatment strategies for MS and supports the ongoing clinical exploration of foralumab. The company is preparing to submit relevant data for peer review to further validate these findings.
Read more →TLSA▲ +14.1%on this news
Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3
Tiziana Life Sciences has announced promising findings regarding its intranasal anti-CD3 monoclonal antibody, which may help reduce side effects commonly associated with the discontinuation of GLP-1 agonists like semaglutide. This therapy not only enhances the benefits of GLP-1 drugs but also assists in maintaining tissue homeostasis even when such medications are stopped. Tiziana’s research suggests that nasal anti-CD3 can mitigate inflammation in various organs, offering a new approach to managing metabolic disorders. This breakthrough could significantly improve treatment outcomes for patients facing challenges with standard GLP-1 therapies.
Read more →TLSATiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab’s Potential in the Treatment of Neurological Disease
Tiziana Life Sciences announced the publication of a review article in Nature Reviews Neurology, highlighting the potential of intranasal foralumab in treating neurodegenerative diseases such as MS, Alzheimer's, ALS, and Parkinson's. The article discusses the immune mechanisms involved and emphasizes the therapeutic promise of targeting microglial activation. Tiziana's CEO expressed optimism about advancing treatments for significant unmet medical needs.
Read more →TLSATiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease
Tiziana Life Sciences announced the publication of a review article in Nature, highlighting its lead candidate, intranasal Foralumab, as potentially effective in treating various neurodegenerative diseases, including Multiple Sclerosis, Alzheimer's, ALS, and Parkinson's. The article discusses how Foralumab can dampen microglial activation, a key factor in these conditions. Notably, the FDA has approved an increase in patient enrollment for ongoing studies, which shows promise in addressing significant unmet medical needs in neurodegenerative disease treatment.
Read more →TLSA▲ +6.5%on this news· ran to -17% by day 3
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer's Disease Dosed with Intranasal Foralumab
Tiziana Life Sciences has announced that they have successfully dosed the first patient with moderate Alzheimer's disease using their drug, intranasal foralumab, at Brigham and Women's Hospital. This milestone is part of a broader clinical development program aimed at addressing Alzheimer's disease through the reduction of neuroinflammation. The treatment offers a unique approach by stimulating T regulatory cells to combat neuroinflammation, differentiating it from traditional Alzheimer's therapies focused on amyloid plaques. The study has garnered financial support from the National Institutes of Health, indicating its potential for further development.
Read more →TLSA▲ +12.1%on this news
Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers
Tiziana Life Sciences has announced the expansion of its Phase 2 clinical trial assessing intranasal foralumab for non-active secondary progressive multiple sclerosis (SPMS) to additional prestigious medical centers in the Northeast U.S. This expansion aims to enhance the trial's reach and collaboration with leading institutions in neurodegenerative therapies. The trial’s objective is to gather high-quality data to support Tiziana's regulatory strategy, amidst the significant unmet need for FDA-approved treatments for SPMS. Early results in the Expanded Access Program have shown promising outcomes in patients treated with foralumab.
Read more →TLSATiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association
Tiziana Life Sciences announced that its grant application to the ALS Association has been approved to fund a 20-patient clinical trial. The study will evaluate the safety and early-stage parameters of its novel therapy, intranasal foralumab, for treating Amyotrophic Lateral Sclerosis (ALS). This grant is part of the Hoffman ALS Clinical Trial Awards Program, which supports early-stage trials in promising ALS therapies. Tiziana aims to halt or slow the progress of ALS through its innovative immunotherapy approach.
Read more →TLSATiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data
Tiziana Life Sciences is set to participate in the BIO-Europe 2024 conference in Stockholm, Sweden from November 4-6. At the conference, they will discuss their recent clinical advancements, notably positive data from their GLP-1 combination study involving the drug Ozempic. This participation is an opportunity for Tiziana to connect with potential partners and investors while highlighting their therapeutic development efforts, particularly in relation to their lead candidate, intranasal foralumab, which shows promise in treating non-active secondary progressive multiple sclerosis. The company aims to further advance its Phase 2 studies following a successful fundraise.
Read more →TLSA▼ -17.4%on this newsshared move
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million
Tiziana Life Sciences has announced a registered direct offering to raise up to $10 million, with an initial $5 million secured. The funds will support a Phase 2a trial for intranasal foralumab in multiple sclerosis and accelerate its development for Alzheimer's disease. The offering is expected to close around November 1, 2024.
Read more →TLSA▲ +15.7%on this newsshared move
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million Includes initial funding of approximately $5 million, as well as the option for additional proceeds of approximately $5 millio
Tiziana Life Sciences announced a registered direct offering to raise up to approximately $10 million, which includes an initial funding of about $5 million. The offering involves the sale of 5,263,158 common shares priced at $0.95 each, with the closing expected on or around November 1, 2024. The company plans to use proceeds for its Phase 2a trial for intranasal foralumab in secondary progressive multiple sclerosis and related developments. Investors also have the option to acquire additional shares for further funding.
Read more →TLSA▲ +15.7%on this newsshared move
Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study
Tiziana Life Sciences announced positive results from a study combining its nasal anti-CD3 antibody, foralumab, with semaglutide, a GLP-1 agonist. The research, conducted at Brigham and Women's Hospital, demonstrated that this combination improves liver homeostasis and reduces inflammation in diet-induced obesity models. Dr. Howard L. Weiner stated that these findings could pave the way for new approaches in treating obesity-related metabolic disorders. Tiziana plans to advance these promising preclinical findings into further clinical development in the future.
Read more →TLSATiziana Life Sciences Ltd ("Tiziana" or "the Company") Update and Interim Results for the Six Months Ended 30 June 2024
Tiziana Life Sciences Ltd (Nasdaq: TLSA) has announced positive interim results for the six months ended June 30, 2024, highlighting advancements in its innovative therapeutic candidates. The company reported promising data from its lead asset, foralumab, in treating non-active Secondary Progressive Multiple Sclerosis (na-SPMS), with encouraging results from expanded access programs. Tiziana has achieved FDA Fast Track designation for its intranasal foralumab, enhancing the development process. The company also reported improvements in fatigue and neuroinflammation measures in clinical trial participants, further supporting its therapeutic potential.
Read more →TLSATiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer's Disease
Tiziana Life Sciences has announced a $4 million grant awarded by the National Institutes of Health to support research on its anti-CD3 monoclonal antibody for Alzheimer's disease. The grant will fund critical studies aiming to modulate immune activity and potentially slow disease progression. Led by Dr. Howard Weiner at Brigham and Women's Hospital, the study is a significant step towards clinical trials and the development of novel treatments for Alzheimer's, a major neurological challenge faced by millions. This initiative reflects Tiziana's commitment to advancing innovative therapies in neurodegenerative conditions.
Read more →TLSA▼ -5.8%on this news
Tiziana Life Sciences Appoints New Chief Executive Officer
Tiziana Life Sciences has appointed Ivor Elrifi as its new Chief Executive Officer, effective immediately. Elrifi brings extensive experience in the biotechnology and pharmaceutical sectors, previously serving as the global head of Patent Groups at respected law firms. The company aims to expedite its clinical trials for intranasal foralumab, a breakthrough therapy targeting non-active Secondary Progressive Multiple Sclerosis, Alzheimer's Disease, and ALS. Under his leadership, Tiziana hopes to enhance its value and accelerate its innovative drug development initiatives.
Read more →TLSA▲ +11.1%on this news
Tiziana Life Sciences Granted FDA Fast Track Designation
Tiziana Life Sciences has received Fast Track designation from the FDA for its intranasal formulation of foralumab, aimed at treating non-active Secondary Progressive Multiple Sclerosis. This designation signifies an expedited review process and promotes closer collaboration with the FDA to address unmet medical needs in neurodegenerative diseases. While this milestone is significant, the company currently faces the risk of delisting from Nasdaq due to not meeting the minimum bid price requirement. Tiziana intends to appeal this decision while advancing its clinical programs.
Read more →TLSAFDA clears foralumab nasal spray for expanded use in Alzheimer’s
The FDA has approved the expanded use of foralumab, a nasal spray developed by Tiziana Life Sciences, for treating moderate Alzheimer's disease. The first patient is set to be dosed this month as part of a compassionate use program. Foralumab aims to reduce neuroinflammation linked to Alzheimer's by targeting immune responses. Previous studies indicate its potential effectiveness in alleviating symptoms.
Read more →TLSATiziana Receives $3.4 Million in Non-Dilutive Funding
Tiziana Life Sciences announced the receipt of $3.4 million in non-dilutive funding to support ongoing clinical trials, particularly for intranasal foralumab used in treating non-active secondary progressive multiple sclerosis (na-SPMS) and Alzheimer's disease. This funding is expected to enhance the company's financial position and allow for expanded research initiatives. The Phase 2 trial for foralumab began patient screening in November 2023, showcasing Tiziana's commitment to innovative therapies in neuroinflammation and neurodegeneration.
Read more →TLSATiziana Life Sciences to Dose First Patient with Moderate Alzheimer's Disease with Foralumab
Tiziana Life Sciences announced that the FDA has granted permission for the use of intranasal foralumab in its first patient suffering from moderate Alzheimer's disease under an Expanded Access IND. This approach aims to provide patients without satisfactory treatment options access to this investigational drug. The company's leadership expressed optimism about foralumab's potential to slow cognitive decline linked to neuroinflammation, an aspect associated with Alzheimer's disease. Additionally, Tiziana is advancing toward a Phase 2 study on early symptomatic Alzheimer's Disease patients.
Read more →TLSAFDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis
Tiziana Life Sciences has announced that the FDA has accepted its submission for Fast Track Designation for intranasal foralumab, aimed at treating non-active secondary-progressive multiple sclerosis (na-SPMS). Foralumab has shown promising results in an Expanded Access Program, with a 70% reduction in fatigue scores among treated patients. The approval would highlight the serious need for effective therapies in na-SPMS, where no treatments are currently available. The Fast Track Designation promises a more efficient development process and increased collaboration with the FDA.
Read more →TLSATiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab
Tiziana Life Sciences reported that 80% of non-active Secondary Progressive Multiple Sclerosis patients showed qualitative improvements in PET imaging after receiving intranasal foralumab for at least six months. The FDA has permitted the enrollment of 20 additional patients in the Expanded Access Program to gather more data. The company has also applied for Orphan Drug Designation for foralumab.
Read more →TLSATiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab Qualitative improvements in PET imaging seen in 80% of non-active Sec
Tiziana Life Sciences announced significant findings in their Expanded Access Program for intranasal foralumab, reporting that 80% of enrolled non-active Secondary Progressive Multiple Sclerosis patients exhibited qualitative improvements in neuroimaging over six months. This data emerged from qualitative assessments of PET imaging that showed a reduction in microglial activity in the majority of subjects. The company aims to advance its intranasal foralumab program further, supported by ongoing studies and an application for Orphan Drug Designation. Tiziana highlights the potential of their novel drug delivery technology in treating neurodegenerative diseases.
Read more →TLSATiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab
Tiziana Life Sciences has announced that it has been invited to apply for a grant from the ALS Association to fund a clinical trial of its investigational therapy, intranasal foralumab. This program aims to develop new ALS treatments, focusing on a 6-month trial involving 20 patients. Positive preliminary results from previous studies suggest promise for the therapy, which seeks to advance novel treatment approaches for ALS. The grant opportunity highlights Tiziana's ongoing commitment to addressing the unmet need for effective ALS therapies.
Read more →TLSATiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research
Tiziana Life Sciences announced that its Scientific Advisory Board Chairman, Dr. Howard L. Weiner, will receive the 'Giants of MS' award for his significant contributions to multiple sclerosis research. The award recognizes his pioneering work in the development of treatments such as intranasal foralumab, which has demonstrated the potential to improve the quality of life for MS patients. The award ceremony took place at the Consortium of Multiple Sclerosis Centers annual meeting, highlighting the impact of Dr. Weiner's research on the field.
Read more →TLSATiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab
Tiziana Life Sciences has filed for Orphan Drug Designation for its intranasal formulation of foralumab to treat non-active secondary progressive Multiple Sclerosis (na-SPMS). If approved, it would be the first therapy for this condition to receive such designation. Initial clinical results are promising, with significant improvements reported in fatigue among treated patients. The FDA will review the application within 90 days, potentially paving the way for exclusive marketing rights and financial incentives for Tiziana.
Read more →TLSA▼ -5.7%on this news
Neurology Live Video Interview: Potential of Nasal Foralumab in Treating Non-Active Secondary Progressive MS: Tarun Singhal, MD, MBBS
Foralumab, an investigational anti-CD3 monoclonal antibody by Tiziana Life Sciences, shows potential in treating non-active secondary progressive multiple sclerosis (na-SPMS). In a small study, patients exhibited clinical stability and reduced microglial activation after treatment. These findings were presented by Dr. Tarun Singhal at the 2024 AAN Annual Meeting, highlighting the need for better understanding of MS progression.
Read more →TLSA▲ +6.5%on this news· ran to -17% by day 3
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
Tiziana Life Sciences has reported promising three-month neuroimaging results for patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with intranasal foralumab. The study demonstrated significant reductions in microglial activation and improvement in White Matter Z scores among treated patients. These findings were presented at the American Academy of Neurology annual meeting and indicate that intranasal foralumab may provide a new therapeutic approach for managing neuroinflammation in MS. Further studies, including a placebo-controlled trial, are planned to explore these effects more comprehensively.
Read more →TLSAMS News Today: Foralumab found to ease fatigue in SPMS patients in access program
Foralumab nasal spray has shown promising results in reducing fatigue for 70% of patients with nonactive secondary progressive multiple sclerosis (SPMS) in an expanded access program. The treatment, which is currently being tested in a Phase 2 clinical trial, has also led to stabilization or improvement in other clinical measures. The FDA has expanded the access program to allow more patients to receive this experimental therapy.
Read more →TLSATiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
Tiziana Life Sciences announced that the FDA has permitted the enrollment of an additional 20 patients in its Expanded Access Program for intranasal foralumab, aimed at treating non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This program expands the total patient count to 30, allowing access to a novel treatment. Early data indicates that patients have stabilized or improved without serious side effects, with notable improvements in fatigue reported. The expansion comes as part of the company’s ongoing efforts to provide innovative therapies where no approved treatments currently exist.
Read more →TLSA▲ +13.2%on this news· ran to +26% by day 3shared move
Neurology Live: Nasal Foralumab Shows Attenuation of Microglial Activation, Clinical Stabilization in Non-Active Secondary Progressive MS With PIRA
An open-label study revealed that nasal foralumab effectively reduced microglial activation and stabilized clinical conditions in patients with non-active secondary progressive multiple sclerosis (na-SPMS). The treatment demonstrated significant improvements in brain imaging and clinical measures of disability and fatigue. Future studies are planned to further assess its efficacy and safety.
Read more →TLSA▲ +13.2%on this news· ran to +26% by day 3shared move
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
Tiziana Life Sciences announced positive results from its Expanded Access Program for non-active secondary progressive multiple sclerosis patients. After six months of treatment with intranasal foralumab, 70% of patients reported improvements in fatigue, while all patients either stabilized or improved in key clinical measures. This highlights the potential of foralumab in addressing significant symptoms of MS.
Read more →TLSA▲ +13.2%on this news· ran to +26% by day 3shared move
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program 70% of Patients in the Expanded Access Program (EAP) Have Seen Measurable Clinical Improve
Tiziana Life Sciences announced positive results from its Expanded Access Program (EAP) for non-active secondary progressive multiple sclerosis (na-SPMS) patients. The data revealed that 70% of patients treated with intranasal foralumab experienced measurable improvements in fatigue after six months. All patients demonstrated stabilization or improvement in key clinical metrics, indicating the potential efficacy of this investigational therapy. The study emphasizes the need for effective treatments addressing debilitating MS symptoms, particularly fatigue.
Read more →TLSATiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
Tiziana Life Sciences announced promising results from a study on intranasal foralumab, which showed its ability to attenuate microglial activation in patients with non-active secondary progressive multiple sclerosis (na-SPMS) and progression independent of relapse (PIRA). The findings were presented at the American Academy of Neurology's Annual Meeting and highlighted the potential of foralumab as a treatment option for this challenging condition. The study demonstrated a qualitative reduction in microglial activation in a significant percentage of patients after treatment.
Read more →TLSATiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today - Intranasal foralumab attenuated microglial activation in patients
Tiziana Life Sciences announced promising results from a study on its intranasal anti-CD3 monoclonal antibody, foralumab, which showed effectiveness in reducing microglial activation in patients with non-active secondary progressive multiple sclerosis (na-SPMS) that progresses independently of relapse. The study highlights a significant unmet need for effective treatments in this category of MS, as no disease-modifying therapies are currently approved. The findings were presented at the Annual Meeting of the American Academy of Neurology and are the first to suggest potential benefits of foralumab for this challenging patient population.
Read more →TLSA▲ +24.8%on this news· ran to +51% by day 3shared move
Neurology Today: Anti-CD3 Antibody Foralumab Shows Promise in PIRA, Measured by Novel PET Ligand
A pilot study presented at the AAN Annual Meeting indicates that the anti-CD3 antibody foralumab may reduce microglial activation in patients with non-active secondary progressive multiple sclerosis (na-SPMS) with progression independent of relapse (PIRA). The study observed significant reductions in brain region activity and stable clinical outcomes among treated patients. However, the small sample size and lack of safety data highlight the need for further research.
Read more →TLSA▲ +24.8%on this news· ran to +51% by day 3shared move
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
Tiziana Life Sciences presented new data on foralumab at the American Academy of Neurology meeting. The study showed that intranasal foralumab significantly reduces microglial activation and stabilizes disease progression in non-active secondary progressive multiple sclerosis patients. The results suggest a promising avenue for treating this patient population, with ongoing trials to further evaluate efficacy.
Read more →TLSA▲ +24.8%on this news· ran to +51% by day 3shared move
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology - Oral presentation of study shows intranasal foralumab attenuates microglial acti
Tiziana Life Sciences presented new quantitative PET imaging data on foralumab at the Annual Meeting of the American Academy of Neurology. The data suggests that foralumab can attenuate microglial activation and stabilize clinical progression in patients with non-active secondary progressive multiple sclerosis (na-SPMS). A notable 83% of patients showed a qualitative reduction in microglial activation after treatment, indicating a significant therapeutic potential. The company is launching further studies to confirm these findings and assess foralumab's effectiveness in slowing disease progression.
Read more →TLSATiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
Tiziana Life Sciences Ltd. announced an upcoming oral presentation on April 17, 2024, at the Annual Meeting of the American Academy of Neurology. The presentation will showcase new quantitative PET imaging data on their lead candidate, Foralumab, as a treatment for non-active Secondary Progressive Multiple Sclerosis (SPMS). Foralumab, a fully human anti-CD3 monoclonal antibody, aims to dampen inflammation by modulating T cell function. The innovative intranasal administration route could enhance the drug's efficacy and tolerability compared to traditional intravenous methods.
Read more →TLSAMS News Today: ECTRIMS 2023: Foralumab seen to ease brain inflammation in SPMS
Foralumab, a nasal anti-CD3 monoclonal antibody, demonstrated potential in reducing brain inflammation in patients with nonactive secondary progressive multiple sclerosis (SPMS). Data presented at the ECTRIMS-ACTRIMS meeting indicated that five out of six patients experienced decreased microglial activity after six months of treatment. The therapy is well tolerated and will progress to Phase 2a testing.
Read more →TLSANeurology Live: Significant Improvements in Progressive Multiple Sclerosis Through Foralumab Treatment
A small-scale study presented at MSMilan 2023 showed that foralumab treatment led to significant improvements in clinical measures for patients with non-active secondary progressive multiple sclerosis (SPMS). Over a 6-month period, patients exhibited stabilization or improvement in various assessments, including the Expanded Disability Status Scale and Modified Fatigue Impact Score. The treatment was deemed safe with minimal adverse effects, and Tiziana Life Sciences plans to initiate a phase 2 study later this year.
Read more →TLSA▲ +9.6%on this news
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease
Tiziana Life Sciences announced a podium presentation at the AD/PD conference, showcasing positive data on their intranasal anti-CD3 monoclonal antibody for Alzheimer's and Parkinson's disease. The research indicates that this treatment reduces microglia activation and improves behavior in rodent models. The approach may complement existing therapies by targeting neuroinflammation directly.
Read more →TLSA▲ +9.6%on this news
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer's Disease Data shows reduction of microglia activation and improvement in behavior in rodent models of Alzheimer's disease (AD)
Tiziana Life Sciences announced that Dr. Howard Weiner will present data on intranasal anti-CD3 monoclonal antibody for Alzheimer's and Parkinson's diseases at the AD/PD conference in Lisbon. The research indicates that this treatment may reduce microglia activation and prevent complications like hemorrhage and edema. The approach targets neuroinflammation, which could complement existing anti-amyloid therapies. Tiziana's treatment represents a novel direction in managing neurodegenerative diseases.
Read more →TLSA▼ -6.8%on this news
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
Tiziana Life Sciences has announced promising results from their updated clinical and PET scan findings for intranasal foralumab in patients with non-active secondary progressive multiple sclerosis. Out of eight evaluated patients, six demonstrated improvements in fatigue as measured by the Modified Fatigue Impact Scale, complemented by PET scan results showing reduced microglial activation. The director of the PET Imaging Program noted a qualitative reduction in microglial activity in one of two additional patients, further supporting the therapy's potential. Tiziana plans to continue with its ongoing Phase 2 trial to further validate these findings.
Read more →TLSATiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
Tiziana Life Sciences Ltd. announced that its COO and CMO, Matthew Davis, will present at the Biotech Showcase Conference in San Francisco from January 8-10, 2024. The presentation will highlight the initiation of a Phase 2 trial using intranasal foralumab, a fully human anti-CD3 monoclonal antibody, aimed at treating non-active secondary progressive multiple sclerosis and other neurodegenerative diseases. The conference serves as a significant networking platform for life science firms and investors.
Read more →TLSATiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity- Associated Inflammation
Tiziana Life Sciences has filed a new patent application for a combination therapy using Foralumab, a fully human anti-CD3 antibody, with GLP-1 receptor agonists. This innovative therapy aims to further reduce systemic and vascular inflammation related to Type 2 Diabetes and obesity. Results from recent studies indicate that the combination could enhance the effectiveness of GLP-1 receptor agonists, which have already demonstrated significant cardiovascular risk reduction. The company is optimistic about the potential impacts of this therapy on patient outcomes.
Read more →TLSATiziana Life Sciences Ltd ("Tiziana" or "the Company") Updated Interim Results for the Six Months Ended 30 June 2023
Tiziana Life Sciences has updated stakeholders on its interim financial results for the six months ended June 30, 2023, highlighting progress in its intranasal foralumab programs targeting CNS-mediated inflammatory diseases. The company has received clearance to proceed with clinical testing for Alzheimer's disease and has seen significant media recognition for its unique therapeutic approach. However, it reported an operating loss of $8.692 million and a net loss of $8.617 million, which has raised concerns regarding its financial position. Overall, while the advancements are promising, the financial losses present a challenge.
Read more →TLSA▲ +5.5%on this news
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
Tiziana Life Sciences has initiated its Phase 2a clinical trial for intranasal foralumab, with the first patient dosed. This trial aims to evaluate the safety and efficacy of the drug in patients with non-active secondary-progressive multiple sclerosis, a condition that currently lacks FDA-approved treatments. Key endpoints include changes in microglial activation and various clinical assessments related to quality of life. The company anticipates crucial insights from the study, which aims to provide a new therapeutic option for patients with an unmet medical need.
Read more →TLSABioWorld: Nasal anti-CD3 antibody improves Alzheimer’s disease in mice
A nasal anti-CD3 monoclonal antibody has been shown to reduce microglia activation and improve cognitive function in mice with Alzheimer's disease. The study, led by Howard Weiner, indicates that the treatment's effects are independent of beta-amyloid deposits, suggesting a novel immunotherapy approach. Future clinical trials will assess its efficacy in humans, particularly in early-stage Alzheimer's patients.
Read more →TLSATiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
Tiziana Life Sciences Ltd. will present at the Webull LIVE! Biotech Investment Webinar on December 6, 2023. The presentation will be led by Matthew Davis, Tiziana's COO and CMO, and will cover updates on the Phase 2 clinical trial of intranasal foralumab for treating neuroinflammatory conditions like non-active secondary progressive multiple sclerosis and Alzheimer’s disease. Tiziana is recognized for its novel immunomodulation therapies and innovative drug delivery systems.
Read more →TLSATiziana Life Sciences Ltd Notice of Annual General Meeting of Shareholders on Thursday 14th December 2023 at 8.30am EST/ 1.30pm UK TO BE HELD AS A "REMOTE MEETING" ONLY YOU ARE NOTIFIED that the 2023 annual general meeti
Tiziana Life Sciences Ltd is set to conduct its Annual General Meeting (AGM) remotely on December 14, 2023, at 8:30 AM EST. Shareholders are encouraged to participate via video or phone and vote on important resolutions, including re-electing a director and reviewing the company's annual accounts. The company has emphasized that the proposed resolutions are in the best interests of all shareholders. The record date for participating shareholders is December 12, 2023.
Read more →TLSATiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
Tiziana Life Sciences has announced the dosing of four new patients with non-active secondary progressive multiple sclerosis as part of its Expanded Access Program. With a total of ten patients now being followed, the program aims to provide critical regulatory evidence for the investigational therapy, foralumab. All patients so far have shown no serious side effects, which supports the drug's safety profile. Additionally, Tiziana is set to begin enrollment for its Phase 2a trial, advancing its mission to improve treatment options for patients with this debilitating condition.
Read more →TLSATiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
Tiziana Life Sciences announced a late-breaking poster presentation at the ECTRIMS Congress, showcasing six-month safety and biomarker data for intranasal Foralumab in patients with non-active secondary progressive multiple sclerosis. The presentation highlights the potential of Foralumab as a novel treatment approach. A Phase 2 trial is set to begin screening in November 2023.
Read more →TLSATiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023
Tiziana Life Sciences Ltd. is set to present recent clinical updates on its intranasal foralumab treatment at the BIO-Europe conference in Munich from November 6-8, 2023. The focus will be on its application for treating non-active secondary progressive multiple sclerosis and other neuroinflammatory diseases. The company is also participating in one-on-one meetings at the event. Foralumab is noted for its innovative delivery method and is the only fully human anti-CD3 monoclonal antibody, which has shown promise in prior clinical studies.
Read more →TLSATiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment
Tiziana Life Sciences has received FDA approval for the at-home dosing of Intranasal Foralumab for multiple sclerosis patients. This groundbreaking decision enhances treatment accessibility and patient convenience, allowing self-administration of the therapy. The initiative aims to improve patient compliance and overall treatment outcomes, marking a significant advancement in multiple sclerosis care.
Read more →TLSATiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment Patients In the Intermediate Size Patient Population Expanded Access (EA) Program Will Receive
Tiziana Life Sciences has received FDA approval for at-home dosing of Intranasal Foralumab for multiple sclerosis patients. This significant milestone allows patients to self-administer the treatment, enhancing convenience and reducing the need for frequent clinic visits. Tiziana's innovative approach is expected to improve patient management of the condition while maintaining the therapy's efficacy and safety. The Phase 2a study of the drug is set to begin in November 2023, underscoring Tiziana's commitment to advancing multiple sclerosis treatment.
Read more →TLSA▲ +6.3%on this news· ran to -18% by day 3shared move
Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab
Tiziana Life Sciences Ltd. has announced positive six-month clinical results for its intranasal foralumab treatment in non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients. Presented at ECTRIMS 2023, the data showcased improvements across multiple clinical measures, including the Modified Fatigue Impact Scale and Expanded Disability Status Scale. The findings suggest stabilization or enhancement in physical functions, contrasting the typical decline seen in this disease state. Experts affiliated with Tiziana expressed optimism about these results, highlighting the challenge of treating na-SPMS and the implications of foralumab's anti-inflammatory properties.
Read more →TLSA▲ +8.1%on this newsshared move
Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)
Tiziana Life Sciences announced promising results from its Expanded Access Program for intranasal foralumab in treating non-active secondary-progressive multiple sclerosis (na-SPMS). Five out of six patients demonstrated a qualitative reduction in microglia activation, a key biomarker. The company plans to initiate Phase 2 clinical trials in November 2023, aiming to provide new treatment options for patients.
Read more →TLSA▲ +8.1%on this newsshared move
Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS) Five out of six patients in FD
Tiziana Life Sciences has reported positive results from a six-month PET scan study involving intranasal foralumab for treating multiple sclerosis patients diagnosed with non-active secondary-progressive MS. The results indicate a reduction in activated microglia in five of the six patients. The findings suggest further investigation is warranted, with a Phase 2a trial expected to commence in November 2023. This innovative approach may provide a new avenue for treating neuroinflammatory and neurodegenerative diseases.
Read more →TLSATiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress Late-breaking p
Tiziana Life Sciences announced the presentation of six-month safety and biomarker data for its intranasal foralumab at the ECTRIMS Annual Congress in Milan. Foralumab is the only fully human anti-CD3 monoclonal antibody, aimed at treating Non-Active Secondary Progressive Multiple Sclerosis. The company emphasizes the innovative nasal route's potential to improve safety and efficacy compared to traditional intravenous delivery. A Phase 2 trial for intranasal foralumab is set to start screening in November 2023, marking a significant step in neuroinflammatory therapies.
Read more →TLSATiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab Numeric improvements were seen across key multiple sclerosis measures, including the Mo
Tiziana Life Sciences announced positive six-month clinical results for intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). The findings show notable improvements in key clinical measures including the Modified Fatigue Impact Scale scores and physical function, indicating potential benefits for this underserved patient population. The safety profile remains favorable and a Phase 2 trial is set to begin screening in November 2023.
Read more →TLSATiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis
Tiziana Life Sciences has commenced a Phase 2a clinical trial of intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Following an Investigator's Meeting at Brigham and Women's Hospital, site initiation for the trial will involve recruiting 6 to 10 clinical trial sites. The trial aims to explore novel endpoints and utilizes a double-blind, randomized placebo control design. Preliminary data from an Expanded Access program shows promising signs of improvement in some patients' PET scans after treatment.
Read more →TLSATiziana Life Sciences to Participate in the H.C. Wainwright 25 th Annual Global Investment Conference
Tiziana Life Sciences Ltd. announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference scheduled for September 11-13, 2023. The company will present virtually and offer one-on-one meetings for prospective investors. Tiziana is known for developing breakthrough immunomodulation therapies, utilizing innovative delivery methods that may improve treatment efficacy and safety. This event is an opportunity for Tiziana to enhance its market visibility and investor engagement.
Read more →TLSATiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Tiziana Life Sciences Ltd. will participate in the H.C. Wainwright 25th Annual Global Investment Conference from September 11-13, 2023. The company will present virtually and hold one-on-one meetings. Tiziana focuses on developing immunomodulation therapies with novel drug delivery methods, particularly their lead candidate, intranasal foralumab, which has shown promising results in clinical studies.
Read more →TLSAStudy Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance
Tiziana Life Sciences announced the publication of a study in PNAS validating the mechanism of action for intranasal foralumab in treating Alzheimer's disease. The FDA has cleared the IND for human studies, highlighting its potential as a non-toxic immunotherapeutic option. The study demonstrated that intranasal anti-CD3 can improve cognition in a rodent model by targeting microglial activation, independent of amyloid beta deposition.
Read more →TLSAStudy Validating MoA of Intranasal Foralumab in Alzheimer's Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance The authors conclude that "nasal anti-CD3 has the potential to be a non-toxic nov
Tiziana Life Sciences announced the publication of a study supporting the mechanism of action of intranasal foralumab as a potential treatment for Alzheimer's disease in the Proceedings of the National Academy of Sciences. The study demonstrates that the therapy ameliorates disease in mouse models by modulating microglial activation, independent of amyloid beta deposition. This second publication on the subject this year, along with FDA IND clearance, opens the door for human trials. Experts consider this a significant advancement in the field of neuroinflammatory diseases.
Read more →TLSATiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology NEW YORK, August 23 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Ti
Tiziana Life Sciences announced an oral presentation by Dr. Howard Weiner at the 16th International Society of Neuroimmunology Congress focused on their candidate, foralumab. The presentation will cover its potential to treat neuroinflammatory diseases such as multiple sclerosis and Alzheimer's disease, emphasizing ongoing research and clinical trials. Recent advancements include successful FDA filings for Alzheimer's and progress in the expanded access program for multiple sclerosis patients. The presentation is scheduled for August 24, 2023, in Quebec City, Canada.
Read more →TLSATiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer Leadership Addition Strengthens Company's Commitment to Advancing Innovative Therapies
Tiziana Life Sciences Ltd. has appointed William A. Clementi as its Chief Development Officer, effective September 1, 2023. Clementi, who possesses extensive experience in drug development and regulatory processes, will oversee the company's strategic development initiatives. His appointment is expected to strengthen Tiziana's commitment to advancing its innovative therapeutic candidates, particularly in immunomodulation therapies. The company is known for its novel drug delivery technologies, including an innovative nasal approach that has demonstrated potential benefits in terms of efficacy and safety.
Read more →TLSATiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology
Tiziana Life Sciences announced an oral presentation on foralumab at the ISNI Congress. Dr. Howard Weiner will discuss its potential in treating neuroinflammatory diseases like MS, AD, and ALS. The company is also advancing its Multiple Sclerosis Expanded Access program and has filed an IND for Alzheimer's. Phase 2 trials for intranasal foralumab are expected to begin soon.
Read more →TLSATiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer
Tiziana Life Sciences has appointed William A. Clementi as Chief Development Officer, effective September 1, 2023. Dr. Clementi brings extensive experience in drug development and regulatory processes, which will enhance Tiziana's efforts in advancing its therapeutic pipeline. His leadership is expected to significantly contribute to the company's growth and commitment to innovative therapies.
Read more →TLSATiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease
Tiziana Life Sciences has announced a live interview featuring Dr. Howard L. Weiner to discuss the FDA's IND clearance for intranasal foralumab in treating Alzheimer's disease. Foralumab, a fully human anti-CD3 monoclonal antibody, aims to modulate neuroinflammation, addressing a significant unmet need in this challenging area of medicine. The interview is part of Tiziana's broader efforts to advance its clinical programs and explore innovative treatment options for neurological conditions. Additionally, a Phase 2 trial for non-active secondary progressive multiple sclerosis is expected to start in Q3 2023.
Read more →TLSANeurology Live Coverage: FDA Clears IND to Test Intranasal Foralumab in Alzheimer Disease
The FDA has cleared Tiziana Life Sciences' IND application for intranasal foralumab to treat Alzheimer's disease. This fully human anti-CD3 monoclonal antibody aims to address neuroinflammation linked to toxic protein accumulation in the brain. The company is set to initiate phase 2 trials, marking a significant step in Alzheimer's research.
Read more →TLSA▲ +36.6%on this newsshared move
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease
Tiziana Life Sciences has received FDA clearance for its Investigational New Drug application for intranasal foralumab, aimed at treating Alzheimer's disease. This therapy, which is the only fully human anti-CD3 monoclonal antibody, is expected to enter Phase 2 clinical trials. The trials will be overseen by Brigham and Women’s Hospital, focusing on the treatment's effectiveness in addressing neuroinflammation associated with Alzheimer's.
Read more →TLSA▲ +36.6%on this newsshared move
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer's Disease Foralumab to advance into Phase 2 human clinical trials using the world's only fully human intranasal ant
Tiziana Life Sciences has announced that the FDA has cleared its IND application for intranasal foralumab to treat Alzheimer's disease. This treatment aims to target the underlying neuroinflammation associated with the disease. The company plans to initiate Phase 2 human clinical trials in non-active secondary progressive multiple sclerosis patients later this year. Tiziana emphasizes its commitment to developing innovative immunomodulation therapies via novel drug delivery methods.
Read more →TLSATiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice New York
Tiziana Life Sciences Ltd. announced receipt of a Nasdaq deficiency notice due to non-compliance with the Minimum Bid Price Requirement. The company must ensure its stock price exceeds $1 for at least ten consecutive business days by January 16, 2024, to maintain its listing. This notification does not indicate imminent delisting, and the company plans to monitor its stock price and take necessary measures to comply with the listing rules. Tiziana develops innovative immunomodulation therapies, including a nasal approach to enhance treatment efficacy and safety.
Read more →TLSATiziana Life Sciences Promotes Matthew W. Davis, MD, RPh to Chief Operating Officer
Tiziana Life Sciences has appointed Matthew W. Davis, MD, RPh as the new Chief Operating Officer. Previously serving as the Chief Medical Officer, Dr. Davis will oversee daily operations, including research and development, as the company works on advancing its therapeutic pipeline. His leadership is expected to significantly influence the company's strategic initiatives and growth. Notably, Tiziana is set to advance its lead asset, foralumab, into a phase 2 trial for non-active secondary progressive multiple sclerosis.
Read more →TLSA▼ -10.7%on this news· ran to -27% by day 3
Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis
Tiziana Life Sciences announced encouraging results from its Expanded Access program for intranasal foralumab, showing a reduction in microglial activation in 5 out of 6 non-active secondary progressive multiple sclerosis patients. This reduction is linked to lowered brain inflammation associated with neurodegenerative diseases. The positive data will support Tiziana's Phase 2a trial set to begin in Q3 2023. The company aims to leverage this promising outcome as they progress further in clinical evaluations.
Read more →TLSA▼ -10.7%on this news· ran to -27% by day 3
T iziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis Results confirm positive
Tiziana Life Sciences has reported a notable reduction in microglial activation in five out of six patients with non-active secondary progressive multiple sclerosis (na-SPMS) using intranasal foralumab. The results, observed in 3-month PET scans, suggest a decrease in brain inflammation which could lead to improved clinical outcomes for these patients. Experts from Brigham and Women's Hospital have commended the findings, indicating their significance in the context of neuroinflammatory diseases. Tiziana is preparing to submit these promising results for publication and anticipates starting a Phase 2a clinical trial later this year.
Read more →TLSATiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS) Webinar to take place on Monday
Tiziana Life Sciences announced it will host a virtual KOL webinar on June 5, 2023, to discuss the potential of foralumab in treating non-active secondary progressive multiple sclerosis (naSPMS). The webinar will feature Howard Weiner, M.D., who will address anti-inflammatory approaches to neurodegenerative diseases. The event will also provide an update on the intranasal foralumab Expanded Access Program and its upcoming Phase 2 trials, expected to start in the third quarter of 2023.
Read more →TLSATiziana Life Sciences Announces Participation on the Webull Corporate Communications Service Platform
Tiziana Life Sciences Ltd. has announced its participation on the Webull Corporate Communication services platform to improve communication with its shareholders. The new portal will provide instant notifications on corporate news, earnings reports, and investor presentations. Gabriel Cerrone, the Interim CEO, expressed enthusiasm about utilizing Webull's mobile-first platform to enhance outreach to active investors. Tiziana is also progressing with its lead candidate, intranasal foralumab, which is expected to enter Phase 2 trials later this year.
Read more →TLSATiziana Life Sciences Announces Chief Medical Officer Invited to Give Presentation on Intranasal Foralumab on May 17
Tiziana Life Sciences announced that its Chief Medical Officer will present on intranasal foralumab at the Hanson Wade Novel Nasal Formulation and Delivery Summit. This presentation showcases the growing interest in Tiziana's innovative immunomodulation therapies, particularly the unique delivery method of the fully human anti-CD3 monoclonal antibody. The company anticipates launching Phase 2 trials for intranasal foralumab in patients with non-active secondary progressive multiple sclerosis in the upcoming quarter, marking a significant step forward for their clinical research. Tiziana's efforts reflect a commitment to alternative immunotherapy approaches and enhancing treatment efficacy.
Read more →TLSA▼ -7.5%on this news
Tiziana Life Sciences Announces Findings from Intranasal Anti-CD3 mAb Treatment in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference There are no effective treatments for intracerebral hemor
Tiziana Life Sciences announced findings on the use of intranasal anti-CD3 monoclonal antibody (mAb) for treating intracerebral hemorrhage at the American Academy of Neurology conference. The study presented positive data supporting the therapeutic potential of this novel approach in a mouse model. Current treatment options for intracerebral hemorrhage are lacking, emphasizing the importance of these findings. Tiziana plans to initiate Phase 2 trials for intranasal foralumab in patients with non-active secondary progressive multiple sclerosis later this year.
Read more →TLSATiziana Life Sciences Ltd Reports Annual Results for the Twelve Months Ended
Tiziana Life Sciences Ltd. reported its annual financial results for the year ending December 31, 2022, along with a corporate update on its leading therapeutic program, intranasal foralumab. The company is focusing on advancing this unique therapy aimed at addressing various CNS-mediated inflammatory diseases, including Long Covid, Alzheimer's, and Type 1 diabetes. Tiziana has positive expectations regarding its Phase 2 trials expected to commence in Q3 2023. The firm emphasizes its innovative drug delivery technologies as key to improving immunotherapy efficacy and safety.
Read more →TLSA▼ -5.8%on this news· ran to -23% by day 3shared move
Tiziana Life Sciences Ltd. Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
Tiziana Life Sciences Ltd. has regained compliance with the Nasdaq listing minimum bid price requirement, after previously being notified of non-compliance in June 2022. The company successfully maintained a closing bid price of at least $1.00 for the required ten consecutive trading days as of April 20, 2023. Tiziana is working on breakthrough immunomodulation therapies utilizing novel drug delivery methods, including its lead candidate intranasal foralumab, which has shown promising clinical results.
Read more →TLSATiziana Life Sciences to File Alzheimer's IND for Intranasal Foralumab in Q2 2023 Application for $3M of non-dilutive funding for Phase 2a Alzheimer's trial will be submitted in Q2 2023 Tiziana guided by FDA Type "B" mee
Tiziana Life Sciences announced its intention to submit an IND for intranasal foralumab in patients with mild to moderate Alzheimer's Disease in Q2 2023. The company aims to investigate the effects of intranasal foralumab on microglia activation and neuroinflammation. Additionally, Tiziana is seeking $3 million in non-dilutive funding to support its Phase 2a trial. This development follows positive feedback from the FDA on the company’s development plans.
Read more →TLSA▲ +8.4%on this newsshared move
Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes CD3 antibody has emerged as an established and attractive target for Type 1 diabetes after the $2.9 billion acquisition of Proven
Tiziana Life Sciences has announced the initiation of a program to develop intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of Type 1 Diabetes. This innovative delivery method may provide significant benefits, including improved patient convenience by enabling self-administration without injections. Upcoming Phase 2 trials are expected to commence in the third quarter of 2023, capitalizing on foralumab's promising safety profile and clinical response in previous studies.
Read more →TLSA▲ +5.9%on this news· ran to +26% by day 3shared move
Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID Long COVID remains a high unmet need causing a myriad of complications for patients and costing the U.S. healthcare syst
Tiziana Life Sciences has announced its intention to pursue the development of intranasal foralumab for treating Long COVID, a condition affecting over 9 million people in the U.S. The intranasal formulation has shown promise in dampening activated microglia, thought to play a crucial role in the condition's pathogenesis. Phase 2a clinical trials are anticipated to commence in Q3 2023, pending positive FDA feedback. This initiative represents a significant step in addressing the healthcare burden associated with Long COVID.
Read more →TLSATiziana Life Sciences Announces Presentations on Intranasal Foralumab at the "Preserving the Brain" Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai Exhibition will run from March 31 st to May 21 st , 202
Tiziana Life Sciences has announced presentations on its lead asset, intranasal Foralumab, at the "Preserving the Brain" conference in Shanghai. This event focuses on neurodegenerative diseases and aims to facilitate dialogue among leading international scientists. Foralumab, a fully human anti-CD3 monoclonal antibody, offers potential treatment options for inflammatory human diseases. Phase 2 trials for intranasal Foralumab are set to commence in Q3 2023, indicating the company's progression in immunomodulation therapies.
Read more →TLSA▼ -21.2%on this newsshared move
Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference Dr. Saef Izzy's data shows one-
Tiziana Life Sciences announced that Dr. Saef Izzy will present pre-clinical data on the effects of intranasal anti-CD3 monoclonal antibody for treating intracerebral hemorrhage at the Annual American Academy of Neurology Conference. The study indicates potential improvements in behavioral outcomes for patients suffering from hemorrhagic stroke by modulating neuroinflammation. Tiziana is actively looking to advance this treatment into human clinical trials, reflecting their commitment to developing innovative therapies.
Read more →TLSA▼ -21.2%on this newsshared move
Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage Tiziana planning to advance foralumab, the only fully human anti-CD3 monoclonal antibody, into human testing for hemo
Tiziana Life Sciences Ltd. has announced positive pre-clinical data regarding its intranasal anti-CD3 monoclonal antibody, foralumab, in the context of intracerebral hemorrhage. Improved motor and cognitive outcomes were observed one month post-treatment in a relevant animal model, leading the company to plan for human clinical trials. This therapy is particularly significant as it addresses the limited recovery rates in hemorrhagic stroke patients. Foralumab is noted for being the first fully human anti-CD3 monoclonal antibody and may represent a breakthrough in immunomodulation therapy.
Read more →TLSATiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer's Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer's and Parkinson's Disease and Related Neuro
Tiziana Life Sciences announced that Dr. Howard Weiner will present positive findings on the use of intranasal anti-CD3 monoclonal antibody for Alzheimer's disease at the AD/PD 2023 conference in Sweden. The research indicates that this approach can decrease microglia activation, potentially enhancing existing Alzheimer's treatments. Tiziana's lead candidate, foralumab, is the only fully human anti-CD3 monoclonal antibody and aims to provide a novel treatment avenue for neuroinflammation. Phase 2 trials are expected to initiate in Q3 2023, focusing on patients with non-active SPMS.
Read more →TLSA▲ +24.4%on this newsshared move
Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) FDA Provides Positive Feedback on Intranasal Foralumab Program in Patients with Non
Tiziana Life Sciences announced its plans to proceed with a Phase 2 clinical trial for intranasal foralumab in patients suffering from non-active Secondary Progressive Multiple Sclerosis (SPMS). This decision follows positive feedback from the FDA during a Type C meeting. The company aims to initiate the trial in the third quarter of 2023, confirming its commitment to advancing this novel therapeutic approach. Foralumab represents a breakthrough in immunomodulation therapies, delivered via an innovative intranasal route.
Read more →TLSA▼ -14.5%on this news
Tiziana Life Sciences Announces Purchase of
Tiziana Life Sciences Ltd. has announced that its Chairman and Acting CEO, Gabriele Cerrone, purchased 8,000 common shares at a price of $0.89 per share, increasing his total holdings significantly. The company, noted for developing immunotherapies via novel delivery methods, is preparing to initiate Phase 2 trials of its lead candidate, intranasal foralumab, in patients with non-active secondary progressive multiple sclerosis later this year. This innovative treatment has shown positive outcomes in prior studies, particularly in relation to inflammation modulation.
Read more →TLSA▲ +11.3%on this newsshared move
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO New York
Tiziana Life Sciences Ltd. has announced that Gabriele Cerrone, the Chairman and Acting CEO, has purchased 7,500 common shares at $0.79 each, increasing his total to 38,693,237 shares. The company is advancing its lead therapeutic candidate, intranasal foralumab, with Phase 2 trials scheduled to begin in Q3 2023 for patients with non-active SPMS. Tiziana’s innovative approaches to immunotherapy through alternative drug delivery methods aim to enhance the safety and efficacy of treatments.
Read more →TLSA▲ +22.4%on this news· ran to +47% by day 1shared move
Tiziana Life Sciences Highlighted in Forbes Article Article entitled "New T Cell Antibody Treatment Improves Outcomes For Covid Patients" reviews the company's first in class foralumab, a unique Intranasal monoclonal ant
Tiziana Life Sciences has been featured in a Forbes article discussing its first-in-class intranasal monoclonal antibody, foralumab. This treatment is currently in clinical development for multiple sclerosis and is noted for its potential benefits in Covid-19 patients. Foralumab, recognized as the only fully human anti-CD3 monoclonal antibody, modulates T cell inflammatory responses, possibly leading to improved health outcomes. Phase 2 trials are anticipated to start in Q3 2023, further exploring this innovative therapeutic approach.
Read more →TLSA▲ +22.4%on this news· ran to +47% by day 1shared move
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting
Tiziana Life Sciences has reported that its Chairman and Acting CEO, Gabriele Cerrone, purchased 25,000 common shares, increasing his total holdings significantly. The company is known for developing novel immunomodulation therapies, particularly its lead candidate, intranasal foralumab. Phase 2 trials for intranasal foralumab are set to begin in Q3 2023 in patients with non-active Secondary Progressive Multiple Sclerosis (SPMS). This strategic share purchase indicates strong confidence in the company's growth and ongoing clinical trials.
Read more →TLSAGrant of share options
Tiziana Life Sciences Ltd. announced the grant of share options to key personnel, including its Chief Medical Officer and Chief Financial Officer, with options priced at $0.57 per share. The options will vest in four tranches over four years, starting in March 2024. The company is developing intranasal foralumab, a fully human monoclonal antibody, with Phase 2 trials set to begin in Q3 2023. This innovative approach aims to enhance immunomodulation for various inflammatory diseases.
Read more →TLSA▲ +5.5%on this news
Tiziana Life Sciences Announces Publication in Proceedings of the National Academy of Sciences (PNAS) Illustrating the Immunological Basis of the Mechanism of Action for Intranasal Foralumab Illustrates that the immunolo
Tiziana Life Sciences announced a publication in the Proceedings of the National Academy of Sciences detailing the mechanism of action for intranasal foralumab. This mechanism has shown consistent modulation of T cell inflammatory responses across individuals with COVID, multiple sclerosis, and healthy volunteers. The company is on track to file an Investigational New Drug (IND) application for Alzheimer's research and initiate Phase 2 trials for multiple sclerosis later this year. Tiziana's intranasal foralumab is being explored for various inflammatory diseases, highlighting its potential therapeutic impact.
Read more →TLSA▲ +8.1%on this news
Tiziana Life Sciences Announces IND filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer
Tiziana Life Sciences Ltd. has announced the filing of an Investigational New Drug (IND) application for a Phase 2 study of milciclib in combination with gemcitabine aimed at treating non-small cell lung cancer (NSCLC). The company reported achieving this milestone with minimal resources, which contributes positively to the asset value and strategic options for milciclib. Previous studies indicated promising efficacy of milciclib both as a standalone treatment and in combination. Tiziana continues to focus on expanding its CNS-focused programs alongside this development.
Read more →TLSATiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab The second Ex
Tiziana Life Sciences announced clinical improvements in the second patient with non-active secondary progressive multiple sclerosis (SPMS) after 11 months of treatment with intranasal foralumab. The patient, referred to as EA2, exhibited a notable decrease in their EDSS score from 6.0 to 5.0, allowing them to walk longer distances without assistance. Medical experts have highlighted the significance of this improvement, as patients with SPMS typically do not experience such a reduction in disability. Tiziana plans to prioritize further development of intranasal foralumab based on these promising results.
Read more →TLSATiziana Life Sciences Ltd ("Tiziana" or "the Company") Updated Interim Results for the Six Months Ended 30 June 2022 London, 29 December 2022 - Tiziana Life Sciences Ltd ("Tiziana", NASDAQ: TLSA), a biotechnology company
Tiziana Life Sciences Ltd ("Tiziana" or "the Company") Updated Interim Results for the Six Months Ended London, 29 December 2022 - Tiziana Life Sciences Ltd ("Tiziana", NASDAQ: TLSA), a biotechnology company enabling breakthrough CNS immunomodulation approaches to enhance th
Read more →TLSATiziana Life Sciences Ltd ("Tiziana" or "the Company") Result of Annual General Meeting London, 29 December 2022 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company") , a biotechnology company developi
Tiziana Life Sciences Ltd ("Tiziana" or "the Company") of Annual General Meeting December 2022 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug deliver
Read more →TLSATiziana Life Sciences Ltd ("Tiziana" or "the Company") Interim Results for the Six Months Ended 30 June 2022 Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unm
Tiziana Life Sciences Ltd ("Tiziana" or "the Company") Interim Results for the Six Months Ended 30 Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need London, 27 December 2022 - Tiziana Life Sciences Ltd ("T
Read more →TLSATiziana to Participate in January Investor Meetings New York
Tiziana to Participate in January Investor Meetings New York, December 16, 2022 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough CNS immunomodulation approaches to enhance the functionality of Treg-based t
Read more →TLSATiziana Life Sciences Announces Completion of Prerequisite Pre-Clinical Safety Study
Sciences Announces Completion of Prerequisite Pre-Clinical Safety Study NEW YORK, Dec. 15, 2022 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delive
Read more →TLSATiziana Life Sciences Ltd. Granted 180-day Extension by Nasdaq to Meet Minimum Bid Price Requirements NEW YORK, /
Life Sciences Ltd. Granted 180-day Extension by Nasdaq to Meet Minimum Bid Price Requirements NEW YORK, / December 14, 2022 / Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough CNS immunomodulation approaches t
Read more →TLSATiziana Life Sciences LTD Notice of Annual General Meeting of Shareholders To be held via video and telephonic conference on
Tiziana Life Sciences LTD Notice of Annual General Meeting of Shareholders To be held via video and telephonic conference on December 29, 2022 at 9.00 a.m. (EST); 2.00pm (U.K.) YOU ARE NOTIFIED that the 2022 annual general meeting ("2022 AGM") of Tiziana Life Sciences LTD (t
Read more →TLSATiziana Life Sciences Announces Date of Annual General Meeting 2022
NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that the 2022 Annual General Meeting of the Company
Read more →TLSATiziana Announces Publication of a Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T cell Function and an Induced T Cell Regulatory Response in Human Subjects Thi
Tiziana Announces Publication of a Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T cell Function and an Induced T Cell Regulatory Response in Human Subjects New York, 23 November 2022 - Tiziana Life Sciences Ltd. (Na
Read more →TLSA▲ +11.3%on this news
Tiziana Life Sciences Announces Near- Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (CNS) - Company to host conference call via webcast at 10 am ET
Life Sciences Announces Near- Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (CNS) conference call via webcast at 10 am ET - NEW YORK, November 10, 2022-- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotech
Read more →TLSATiziana Life Sciences to Host Investor Call
Life Sciences to Host Investor Call YORK, November 04, 2022-- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the Company
Read more →TLSATiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman New York
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman 3, 2022 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces th
Read more →TLSATiziana Life Sciences Completes Enrollment of the First Patient Cohort for its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients
Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients NEW YORK, November 02, 2022 -- Tiziana Life Sciences Ltd. (Nasd
Read more →TLSATiziana Life Sciences Starts Enrollment of the First Patient Cohort in its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients
Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple NEW YORK, October 26, 2022 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or
Read more →TLSAEnabling Breakthrough Immunomodulation Approaches to Enhance the Functionality of Treg - Based Therapies NASDAQ: TLSAx Tiziana Life Sciences Overview | June 2022 2 Disclaimer and Forward - Looking Statement The content o
Enabling Breakthrough Immunomodulation Approaches to Enhance the Functionality of Treg - Based Therapies NASDAQ: TLSAx Tiziana Life Sciences Overview | June 2022 2 Disclaimer and Forward - Looking Statement The content of this presentation has been prepared for the purpose of pr
Read more →TLSATiziana Life Sciences Ltd Invites You to Join Us at The ThinkEquity Conference New York
Tiziana Life Sciences Ltd Invites You to Join Us at The ThinkEquity Conference New York- October 19, 2022 - Tiziana Life Sciences Ltd (NASDAQ: TLSA), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, will be participa
Read more →TLSATiziana Life Sciences Plans to Submit IND for Phase 1 Trial of Intranasal Foralumab in Alzheimer's Disease Patients - Company continues to advance foralumab in CNS-related inflammatory diseases
Life Sciences Plans to Submit IND for Phase 1 Trial of Intranasal Foralumab in Alzheimer's Disease Patients NEW YORK, Oct. 12, 2022 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation thera
Read more →TLSATiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer New York
Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer New York, September 29, 2022 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug del
Read more →TLSATiziana Life Sciences Announces Presentations on Intranasal Foralumab at the "Preserving the Brain" Scientific Conference and Exhibit at the Fondazione Prada in Milan - " Effect of nasal anti-CD3 (foralumab) in animal mo
Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the "Preserving the Brain" Scientific Conference and Exhibit at the Fondazione Prada in Milan - " Effect of nasal anti-CD3 (foralumab) in animal model of Progressive Multiple Sclerosis (MS)" poster exhibi
Read more →TLSATiziana Life Sciences Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) After Six Months of Dosing with Intranasal Foralumab - The second Expanded Access
Life Sciences Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) After Six Months of Dosing with Intranasal Foralumab NEW YORK, Sept. 20, 2022 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Compa
Read more →TLSATiziana Life Sciences Announces Grant received by the Brigham and Women's Hospital to Explore the Use of Intranasal anti-CD3 mAb in Amyotrophic Lateral Sclerosis - Prestigious ALS Association grant awarded to BWH to stud
Tiziana Life Sciences Announces Grant received by the Brigham and Women's Hospital to Explore the Use of Intranasal anti-CD3 mAb in Amyotrophic Lateral Sclerosis - Prestigious ALS Association grant awarded to BWH to study the utility of an intranasal anti-CD3 monoclonal anti
Read more →TLSATiziana Life Sciences Announces Presentation at Alzheimer's Association International Conference 2022 (AAIC ) Evaluating Intranasal anti-CD3 for the Potential Treatment of Alzheimer's Disease - Study conducted in animal
Tiziana Life Sciences Announces Presentation at Alzheimer's Association International Conference 2022 (AAIC ) Evaluating Intranasal anti-CD3 for the Potential Treatment of New York, August 1, 2022 - Tiziana Life Sciences Ltd.(Nasdaq: TLSA) ("Tiziana" or the "Company"), a bio
Read more →TLSATiziana Life Sciences Appoints Matthew W. Davis, MD, RPh as Chief Medical Officer and Acting Chief Scientific Officer New York
Tiziana Life Sciences Appoints Matthew W. Davis, MD, RPh as Chief Medical Officer and Acting Chief Scientific Officer New York, July 18, 2022 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapie
Read more →TLSA▲ +6.6%on this newsshared move
Tiziana Life Sciences Announces Resignation of CEO New York
Life Sciences Announces Resignation of CEO York, July 15, 2022 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that the Board of Directors
Read more →TLSATiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice
NEW YORK, June 17, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of monoclonal antibody delivery, today disclosed the receipt of a notice (the “Notice”) on
Read more →TLSA▼ -6%on this news
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
NEW YORK, June 10, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limi
Read more →TLSATiziana Life Sciences PLC (TLSA: NASDAQ) Releases Research Report: Clinical Improvements for 2nd SPMS Patient
Zacks Small-Cap Research Note By John D. Vandermosten, CFA NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences PLC (NASDAQ: TLSA) announced positive clinical results for its second secondary progressive multiple sclerosis (SMPM) patient in a June 8th press release
Read more →TLSATiziana Life Sciences PLC (TLSA: NASDAQ) Clinical Improvements for 2nd SPMS Patient
Clinical Results for Second SPMS Patient NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences PLC (NASDAQ: TLSA) announced positive clinical results for its second secondary progressive multiple sclerosis (SMPM) patient in a June 8th press release. The ~40 year old
Read more →TLSATiziana Life Sciences Announces An Interview on Clinical Improvements for 2nd SPMS Patient
NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug administration, today announces an interview with Chief Executive Officer and Chie
Read more →TLSA▲ +8.3%on this newsshared move
Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab
A second patient also showed clinical improvements in the Positron Emission Tomography (PET) imaging analysis, neurologic exam, and in the Timed 25-Foot Walk test, following three months of treatment. These findings are consistent with the results obtained from the first patient
Read more →TLSATiziana Life Sciences to Present at the 2022 Biotechnology Innovation Organization Annual Convention to Discuss Recent Updates to Ongoing Clinical Programs
NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company enabling breakthrough immunotherapies via novel routes of administration today announced that its Chief Executive Officer
Read more →TLSATiziana Life Sciences Ltd. Announces Annual Report Filed to Regain Nasdaq Compliance
NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of monoclonal antibody delivery, announced today that it filed its Annual Report on Form 20
Read more →TLSATiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference NEW YORK - 26 April 2022 - Tiziana Life Sciences Ltd (NASDAQ: TLSA) (" Tiziana " or the " C
Tiziana Life Sciences to participate in a Fireside At the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference NEW YORK - 26 April 2022 - Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company developing
Read more →TLSAFDA Grants Permission to Enroll up to 8 Additional Secondary Progressive Multiple Sclerosis (SPMS) Patients in the Expanded Access Program with Intranasal Foralumab This Intermediate-Size Patient Population Expanded Acce
Permission to Enroll up to 8 Additional Secondary Progressive Multiple Sclerosis (SPMS) Patients in the Expanded Access Program with Intranasal Foralumab April 5, 2022 - Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakth
Read more →TLSATiziana Announces Initiation of Phase 1b Clinical Trial in Crohn's Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody This clinical trial, the first-ever oral immunotherap
Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohn's Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody New York, March 25, 2022 - Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology
Read more →TLSA▼ -7.2%on this news
Tiziana Announces Availability of March 14 KOL Event Replay New York
Announces Availability of March 14 KOL Event Replay New York, March 15, 2022 - Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, announces the availability of the
Read more →TLSA▲ +8.8%on this newsshared move
Tiziana Life Sciences Hosting Key Opinion Leader Virtual Event to Discuss the Intranasal Delivery of Foralumab in Multiple Sclerosis Monday, March 14 th @ 11 am ET, registration details below
Tiziana Life Sciences Hosting Key Opinion Leader Virtual Event to Discuss the Intranasal Delivery of Foralumab in Multiple Sclerosis Monday, March 14th @ 11 am ET, registration NEW YORK, March 11, 2022 - Tiziana Life Sciences Ltd (Nasdaq: TLSA) ("Tiziana" or the "Company"), a
Read more →TLSA▲ +30.4%on this news· ran to +42% by day 1shared move
Tiziana Announces Positive Clinical Data from A Secondary Progressive Multiple Sclerosis Patient Treated for Six Months with Intranasally Administered Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody Intranasal fora
Announces Positive Clinical Data from A Secondary Progressive Multiple Sclerosis Patient Treated for Six Months with Intranasally Administered Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody York, March 10, 2022 - Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Co
Read more →TLSA▲ +18.6%on this news· ran to +41% by day 3
StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort New York
Demonstrates Prognostic Utility in TransATAC Cohort New York, March 1, 2022 - Tiziana Life Sciences Ltd.'s (Nasdaq: TLSA) former subsidiary, AccuStem Sciences, Inc. (OTC PINK: ACMSY) (formerly AccuStem Sciences Ltd.), today announced publication of new data in the European Jou
Read more →TLSATiziana Life Sciences plc ("Tiziana" or "the Company") Interim Results for the Six Months Ended 30 June 2021 Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unm
Results for the Six Months Ended 30 June 2021 pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need 24 September 2021 - Tiziana Life Sciences plc ("Tiziana", LSE: TILS, NASDAQ: TLSA), a biotechnology company a biotechnology
Read more →TLSA▲ +5.7%on this news
Tiziana Life Sciences CEO to Present at Annual BIO CEO & Investor Conference
Tiziana Life Sciences CEO to Present at Annual BIO CEO & Investor Conference February 10, 2022, New York, NY - Tiziana Life Sciences Ltd (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug deliver
Read more →TLSATiziana Announces Submission of Amendment to Investigational New Drug Application to Advance Oral Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, in Patients with Crohn's Disease - Tiziana is Developing the First
Tiziana Announces Submission of Amendment to Investigational New Drug Application to Advance Oral Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, in Patients with Crohn's is Developing the First Oral Form of Foralumab in a Convenient Capsule to be Evaluated in Phase 1b C
Read more →TLSA▼ -7.1%on this news
Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Oncology Conference NEW YORK - 26 January 2022 - Tiziana Life Sciences Ltd (NASDAQ: TLSA) (" Tiziana " or the " Company "), a clinic
Tiziana Life Sciences to participate in a Fireside At the B. Riley Securities 2022 Oncology Conference NEW YORK - 26 January 2022 - Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company developing breakthrough therap
Read more →TLSATiziana Life Sciences Ltd. To Implement Stock Repurchase Program for up to $5 Million New York, New York
Tiziana Life Sciences Ltd. To Implement Stock Repurchase Program for New York, New York, January 24, 2022 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced that its Board of Directors has today authorized the Company's management to implement a stock repurchase program for
Read more →TLSA▼ -6.8%on this news
Tiziana Life Sciences Announces Death of Director New York
Tiziana Life Sciences Announces Death of Director New York, January 13, 2022 - Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that Dr. Thomas Adams passed away o
Read more →TLSA▼ -6.8%on this news
Tiziana Life Sciences Announces Death of Director
NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that Dr. Thomas Adams passed away on January 9, 2022. He served as a memb
Read more →TLSA▼ -5.9%on this news· ran to -17% by day 3shared move
Tiziana Enrolls Second Patient in Ongoing Intranasal Foralumab Evaluation for Secondary Progressive Multiple Sclerosis - Clinical data from the first patient, after completing 3 out of 6 months, suggest that the treatmen
Tiziana Enrolls Second Patient in Ongoing Intranasal Foralumab Evaluation for Secondary Progressive Multiple Sclerosis New York, January 10, 2022 - Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies
Read more →TLSATiziana Life Sciences to Participate in 2022 Biotech Showcase Virtual Investor Conference
Tiziana Life Sciences to Participate in 2022 Biotech Showcase Virtual Investor Conference NEW YORK, January 6, 2022 - Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today annou
Read more →TLSA▼ -9.6%on this news
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR
ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFO
Read more →TLSA▲ +12.9%on this newsshared move
PDMR Dealing London, New York, 20 October 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ( Tiziana or the Company ), a biotechnology company focused on innovative therapeutics for oncology, inflammation and
London, New York, 20 October 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified that P
Read more →TLSA▲ +12.9%on this newsshared move
Tiziana Life Sciences plc: PDMR Dealing
LONDON and NEW YORK, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has bee
Read more →TLSA▲ +12.9%on this newsshared move
Tiziana Life Sciences - Scheme Effective Date
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE I
Read more →TLSATiziana Life Sciences plc: Court Sanctions the Scheme of Arrangement and approves Reduction of Capital
LONDON and NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Old Tiziana") a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases announced on 20 August 2021 that it had forma
Read more →TLSAPDMR Dealing London, New York, 6 October 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ( Tiziana or the Company ), a biotechnology company focused on innovative therapeutics for oncology, inflammation and i
London, New York, 6 October 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified that Pa
Read more →TLSAPDMR Dealing London, New York, 5 October 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ( Tiziana or the Company ), a biotechnology company focused on innovative therapeutics for oncology, inflammation and i
York, 5 October 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified that Panetta Partne
Read more →TLSAPDMR Dealing London, New York, 4 October 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ( Tiziana or the Company ), a biotechnology company focused on innovative therapeutics for oncology, inflammation and i
London, New York, 4 October 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified that Pa
Read more →TLSA▼ -6.4%on this news
PDMR Dealing London, New York, 28 September 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (" Tiziana " or the " Company "), a biotechnology company focused on innovative therapeutics for oncology, inflammat
London, New York, 28 September 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified that
Read more →TLSATiziana Life Sciences Plc - Results of Court Meeting and General Meeting
LONDON, Sept. 27, 2021 (GLOBE NEWSWIRE) -- On 20 August 2021, Tiziana Life Sciences Plc (“Old Tiziana”) announced that it has formally commenced its strategic plan to change its corporate structure by establishing Tiziana Life Sciences Ltd (“New Tiziana”), a Bermuda-incorporated
Read more →TLSASeptember 2021 RESULTS OF COURT MEETING AND GENERAL MEETING On 20 August 2021, Tiziana Life Sciences Plc (" Old Tiziana ") announced that it has formally commenced its strategic plan to change it
OF COURT MEETING AND GENERAL MEETING 20 August 2021, Tiziana Life Sciences Plc ("Old Tiziana") announced that it has formally commenced its strategic plan to change its corporate structure by establishing Tiziana Life Sciences Ltd ("New Tiziana"), a Bermuda-incorporated compan
Read more →TLSA▼ -5%on this newsshared move
Notes to the Interim Financial Statements for the six month period to 30 June 2021 Tiziana Life Sciences plc ("Tiziana" or "the Company") Interim Results for the Six Months Ended 30 June 2021 Advancing pipeline of next g
Notes to the Interim Financial Statements six month period to 30 June 2021 ("Tiziana" or "the Company") Results for the Six Months Ended 30 June 2021 pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need 24 September 202
Read more →TLSA▼ -5%on this newsshared move
Tiziana Life Sciences plc - Interim Results for the Six Months Ended 30 June 2021
LONDON, Sept. 24, 2021 (GLOBE NEWSWIRE) -- London, 24 September 2021 – Tiziana Life Sciences plc (“Tiziana”, LSE: TILS, NASDAQ: TLSA), a biotechnology company a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases today anno
Read more →TLSATiziana Life Sciences plc Change of Registered Office London/New York, 7 September 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (" Old Tiziana ") a biotechnology company focused on innovative therapeutics
Tiziana Life Sciences plc Change of Registered Office London/New York, 7 September 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Old Tiziana") a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases announ
Read more →TLSATiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment NEW YORK
to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment YORK and LONDON, September 7, 2021 - Tiziana Life Sciences plc (NASDAQ: TL
Read more →TLSATiziana Life Sciences plc Posting of Scheme Document and Notice of Meetings
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE I
Read more →TLSA▲ +21.2%on this newsshared move
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Tr
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment Precision Gains Access to Tiziana's Anti-CD3 Ant
Read more →TLSATiziana Life Sciences plc files scheme of arrangement to effect a corporate reorganisation and, if approved, the delisting of its ordinary shares in London and the direct listing of common shares in the new parent compan
Tiziana Life Sciences plc files scheme of arrangement to effect a corporate reorganisation and, if approved, the delisting of its ordinary shares in London and the direct listing of common shares in the new parent company of the Tiziana group on NASDAQ London/New York, August
Read more →TLSATiziana Announces Publication of a Peer Reviewed Article on Data from the Clinical Trial with Intranasally Administered Foralumab, Its Proprietary Fully Human Anti-CD3 Monoclonal Antibody, in Mild to Moderate COVID-19 Pa
Tiziana Announces Publication of a Peer Reviewed Article on Data from the Clinical Trial with Intranasally Administered Foralumab, Its Proprietary Fully Human Anti-CD3 Monoclonal Antibody, in Mild to Moderate COVID-19 Patients in Brazil New York/London, August 17, 2021 - Tizia
Read more →TLSATiziana Life Sciences plc Invites You to Join Us at the Q3 Virtual Investor Summit NEW YORK & LONDON
Life Sciences plc Invites You to Join Us at the Q3 Virtual Investor Summit YORK & LONDON, August 16, 2021 - Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, neurology, infl
Read more →TLSATiziana Life Sciences plc ADS Ex-Dividend Date Scheduled for July, 09 2021 THIS ANNOUNCEMENT IS FOR US ADS HOLDERS ONLY New York, 8 July 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA) ( Tiziana or the Company ), a biote
Tiziana Life Sciences Date Scheduled for July, 09 2021 IS FOR US ADS HOLDERS ONLY New York, 8 July 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectio
Read more →TLSATiziana Life Sciences plc Distribution Dates for shares and ADRs in Accustem Sciences Limited London, New York, 2 July 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechno
for shares and ADRs in Accustem Sciences Limited London, New York, 2 July 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, to
Read more →TLSADr Howard Weiner, Chairman of the Tiziana Scientific Advisory Board, to give an interview on Bloomberg Markets at 1.50pm ET today. NEW YORK & LONDON
Dr Howard Weiner, Chairman of the Tiziana Scientific Advisory Board, to give an interview on Bloomberg Markets at 1.50pm ET today. NEW YORK & LONDON, June 30, 2021 - Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutic
Read more →TLSATiziana Life Sciences plc (the "Company") Result of Annual General Meeting
LONDON, June 25, 2021 (GLOBE NEWSWIRE) -- At the Annual General Meeting of the Company held at 10.00 a.m. on 25 June 2021, all of the resolutions were duly passed. The results of the proxy voting will be available shortly on the Company's website, https://ir.tizianalifesciences.
Read more →TLSATHE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTI
THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE REL
Read more →TLSATiziana Enters a Collaboration Agreement with FHI Clinical to Conduct a Phase 2 Clinical Trial for Treating Hospitalized Severe COVID-19 Patients with Intranasal Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody NEW
Tiziana Enters a Collaboration Agreement with FHI Clinical to Conduct a Phase 2 Clinical Trial for Treating Hospitalized Severe COVID-19 Patients with Intranasal Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody NEW YORK & LONDON, June 23, 2021 - Tiziana Life Sciences plc
Read more →TLSATiziana Appoints Dr. Kevin Schutz as Vice-President of Regulatory Affairs NEW YORK & LONDON
Tiziana Appoints Dr. Kevin Schutz as Vice-President of Regulatory Affairs NEW YORK & LONDON, June 21, 2021 - Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious di
Read more →TLSATiziana Responds to UK Call for Development of Innovative Take Home' Treatments for COVID-19 Disease NEW YORK & LONDON
Tiziana Responds to UK Call for Development of Innovative Take Home' Treatments for COVID-19 Disease NEW YORK & LONDON, June 17, 2021 - Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, neurology, inf
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the “Company”) Posting of Notice of Annual General Meeting
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISD
Read more →TLSANOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOUL
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURI
Read more →TLSATiziana Reports Data Indicating Significant Immunomodulation effects on Immune and Inflammatory Biomarkers with Nasally Administered Foralumab in Healthy Volunteers. New York/London, 26 May 2021 - Tiziana Life Sciences p
Tiziana Reports Data Indicating Significant Immunomodulation effects on Immune and Inflammatory Biomarkers with Nasally Administered Foralumab in Healthy Volunteers. New York/London, 26 May 2021 - Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) ("Tiziana" or the "Company")
Read more →TLSATiziana Life Sciences Announces Initiation of Clinical Trial in a Secondary Progressive Multiple Sclerosis (SPMS) Patient with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Indiv
Tiziana Life Sciences Announces Initiation of Clinical Trial in a Secondary Progressive Multiple Sclerosis (SPMS) Patient with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program New York/London, 25
Read more →TLSATiziana Life Science plc PDMR Dealing London, New York, 21 May 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ( Tiziana or the Company ), a biotechnology company focused on innovative therapeutics for oncolo
Tiziana Life Science plc London, New York, 21 May 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it ha
Read more →TLSATiziana Life Sciences Interview to Air on Bloomberg Television U.S. on the RedChip Money Report NEW YORK & LONDON
Tiziana Life Sciences Interview to Air on Bloomberg Television U.S. on the RedChip Money Report NEW YORK & LONDON, May 7, 2021 - Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infe
Read more →TLSATiziana Announces Strategic Initiative with Takanawa Japan K.K., Pharma Team, to Identify a Partner in Japan and Other Asian Countries for Further Clinical Development of Milciclib in Patients with Advanced Hepatocellula
Tiziana Announces Strategic Initiative with Takanawa Japan K.K., Pharma Team, to Identify a Partner in Japan and Other Asian Countries for Further Clinical Development of Milciclib in Patients with Advanced Hepatocellular Carcinoma. Objective of this partnership with Takanawa
Read more →TLSATiziana Life Sciences to participate in a Fireside Chat on 28 April 2021 at 10:30 a.m. EDT NEW YORK and LONDON - 27 April 2021 (GLOBE NEWSWIRE) - Tiziana Life Sciences plc (NASDAQ: TLSA/ LSE: TILS) ( Tiziana or the Compa
Tiziana Life Sciences to participate in a Fireside on 28 April 2021 at 10:30 a.m. EDT NEW YORK and LONDON - 27 April 2021 (GLOBE NEWSWIRE) - Tiziana Life Sciences plc (NASDAQ: TLSA/ LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therape
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Life Sciences plc Announces Plans to List Accustem Sciences Limited in the U.S. N EW YORK and LONDON
Tiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Life Sciences plc Announces Plans to List Accustem Sciences Limited in the U.S. YORK and LONDON , April 13, 2021 - Tiziana Life Sciences plc (NASDAQ: TLSA; LSE: TILS), today announced that its former subsidiary,
Read more →TLSATiziana Life Sciences plc Announces Plans to List Accustem Sciences Limited in the U.S.
NEW YORK and LONDON, April 13, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA; LSE: TILS), today announced that its former subsidiary, Accustem Sciences Limited ("Accustem"), intends to file a listing application with the Nasdaq Stock Market shortly after complet
Read more →TLSATiziana Announces the FDA Has Allowed Treatment for a Secondary Progressive Multiple Sclerosis (SPMS) Patient for the Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Pat
Tiziana Announces the FDA Has Allowed Treatment for a Secondary Progressive Multiple Sclerosis (SPMS) Patient for the Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program New York/London, 30 March 20
Read more →TLSATiziana Plans Phase 2 Clinical Study in Moderate to Severe Covid-19 Patients with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody Since the anti-inflammatory effect of the nasally administer
Tiziana Plans Phase 2 Clinical Study in Moderate to Severe Covid-19 Patients with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody New York/London, 30 March 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a
Read more →TLSATiziana Life Sciences plc: Accustem Update
NEW YORK and LONDON, March 30, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences. (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, is pleased to confirm that, in order to finalise the distribut
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Gabriele Cerrone, Chairman of Tiziana Life Sciences, to give interview on Bloomberg Television US at 1:20 PM ET Today NEW YORK and LONDON - 29 March 2021 - Tiziana L
Tiziana Life Sciences plc ("Tiziana" or the "Company") Gabriele Cerrone, Chairman of Tiziana Life Sciences, to give interview on Bloomberg Television US at 1:20 PM ET Today NEW YORK and LONDON - 29 March 2021 - Tiziana Life Sciences. (NASDAQ: TLSA; LSE: TILS), a biotechnolog
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Updated - Gabriele Cerrone, Chairman of Tiziana Life Sciences to give interview on Bloomberg Television US at 1:50 PM ET Tomorrow, 30 March 2021 NEW YORK and LONDON
Tiziana Life Sciences plc ("Tiziana" or the "Company") Updated - Gabriele Cerrone, Chairman of Tiziana Life Sciences to give interview on Bloomberg Television US at 1:50 PM ET Tomorrow, 30 March 2021 NEW YORK and LONDON - 29 March 2021 - Tiziana Life Sciences (NASDAQ: TLSA;
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Life Sciences Interview to Air on Bloomberg Television US on the RedChip Money Report NEW YORK and LONDON - 26 February 2021 - Tiziana Life Sciences. (NASDAQ
Tiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Life Sciences Interview to Air on Bloomberg Television US on the RedChip Money Report NEW YORK and LONDON - 26 February 2021 - Tiziana Life Sciences. (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on
Read more →TLSATiziana Life Sciences Interview to Air on Bloomberg Television US on The RedChip Money Report
NEW YORK and LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced that an interview with its CEO, Dr Kunwar Shailu
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Life Sciences to Present at the BIO CEO & Investor Digital Conference NEW YORK and LONDON - 16 February 2021 (GLOBE NEWSWIRE) - Tiziana Life Sciences plc (NA
Tiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Life Sciences to Present at the BIO CEO & Investor NEW YORK and LONDON - 16 February 2021 (GLOBE NEWSWIRE) - Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology comp
Read more →TLSATiziana Life Sciences to Present at the BIO CEO & Investor Digital Conference
NEW YORK and LONDON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced that it is pre
Read more →TLSAPDMR DEALING 5 February 2021 NEW YORK and LONDON
NEW YORK and LONDON - February 5, 2021 (GLOBE NEWSWIRE) - Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces the foll
Read more →TLSAAPPOINTMENT OF DIRECTOR 5 February 2021 NEW YORK and LONDON
APPOINTMENT OF DIRECTOR NEW YORK and LONDON - February 5, 2021 (GLOBE NEWSWIRE) - Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases,
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") - Appointment of Director
NEW YORK and LONDON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces the appointmen
Read more →TLSATiziana Life Sciences CEO Discusses COVID-19 Trial Data in Exclusive Interview NEW YORK and LONDON
Life Sciences CEO Discusses COVID-19 Trial Data in Exclusive Interview YORK and LONDON - February 3, 2021 (GLOBE NEWSWIRE) - Tiziana Life Sciences plc (NASDAQ:TLSA/LSE:TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, i
Read more →TLSATHIS ANNOUNCEMENT INCLUDES INSIDE INFORMATION Tiziana Reports Positive Data from the Clinical Study of Nasal Administration with Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, in COVID-19 Patients i
ANNOUNCEMENT INCLUDES INSIDE INFORMATION Reports Positive Data from the Clinical Study of Nasal Administration with Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, in COVID-19 Patients in Brazil York/London, 2 February 2021 - Tiziana Life Sciences plc (Nas
Read more →TLSATiziana Reports Positive Data from the Clinical Study of Nasal Administration with Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, in COVID-19 Patients in Brazil
Since the anti-inflammatory effect of the nasally administered Foralumab is through the modulation of the immune system and not by directly targeting COVID-19, this therapeutic approach might also be useful for newly identified Covid-19 variants in UK, South Africa and Brazil. F
Read more →TLSATiziana Life Sciences plc (" Tiziana " or the " Company ") Tiziana files Registration Statement on Form F-3 with U.S. Securities and Exchange Commission New York / London
Tiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana files Registration Statement on Form F-3 with U.S. Securities and Exchange Commission New York / London, January 27, 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS), a biotechnology company focused on
Read more →TLSAUpdated corporate presentation 26 January 2021 New York/London, 26 January 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeut
Updated corporate presentation New York/London, 26 January 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, has today publis
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") AIM Delisting and Admission to the Standard Listing Segment of Main Market New York/London, 20 January 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("
AIM Delisting and Admission to the Standard Listing Segment of Main Market York/London, 20 January 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, a
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Life Sciences to Participate in a Fireside Chat at B. Riley Virtual Oncology Investor Conference: on 21 January 2021 at 3 pm ET/8 pm GMT NEW YORK and LONDON
Tiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Life Sciences to Participate in a Fireside Chat at B. Riley Virtual Oncology Investor Conference: on 21 January 2021 at 3 pm ET/8 pm GMT NEW YORK and LONDON - 20 January 2021 (GLOBE NEWSWIRE) - Tiziana Life Scie
Read more →TLSATiziana Life Sciences to Participate in a Fireside Chat at B. Riley Virtual Oncology Investor Conference on 21 January 2021 at 3 pm ET/8 pm GMT
NEW YORK and LONDON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced its CEO and CSO
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer New York/London, 13 January 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / A
Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer New York/London, 13 January 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology
Read more →TLSATiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer
NEW YORK and LONDON, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the appointment of D
Read more →TLSATiziana Life Sciences plc ( Tiziana or the Company ) Tiziana Life Sciences to participate at J.P. Morgan Healthcare Conference 2021 NEW YORK and LONDON - 11 January 2021 (GLOBE NEWSWIRE) - Tiziana Life Sciences plc (NASD
Tiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Life Sciences to participate at J.P. Morgan Healthcare Conference 2021 NEW YORK and LONDON - 11 January 2021 (GLOBE NEWSWIRE) - Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a
Read more →TLSATiziana Life Sciences to participate at J.P. Morgan Healthcare Conference 2021
NEW YORK and LONDON, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced that it is par
Read more →TLSATiziana Life Sciences to Present at Biotech Showcase Digital 2021
NEW YORK and LONDON, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced that it is par
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana announces completion of the clinical trial with nasally administered Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, for the treatment o
Tiziana announces completion of the clinical trial with nasally administered Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, for the treatment of COVID-19 patients in Brazil 4 January 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" o
Read more →TLSAThis announcement is an advertisement and not a prospectus. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any
announcement is an advertisement and not a prospectus. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Investors should not purchase any transferable s
Read more →TLSATiziana Life Sciences PLC (“Tiziana” or “the Company”) - Publication of Prospectus
This announcement is an advertisement and not a prospectus. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Investors should not purchase any transferabl
Read more →TLSATiziana Life Sciences PLC ("Tiziana" or "the Company") Notification of proposed admission to the Main Market and cancellation of trading on AIM London, New York, 17 December 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA
Tiziana Life Sciences PLC ("Tiziana" or "the Company") Notification of proposed admission to the Main Market and cancellation of trading on AIM London, New York, 17 December 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechno
Read more →TLSAPDMR Dealing London, New York, 10 December 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (" Tiziana " or the " Company "), a biotechnology company focused on innovative therapeutics for oncology, inflammati
London, New York, 10 December 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified that
Read more →TLSATiziana Life Sciences to Host Investor Update Call on 2 December 2020 at 4:15 p.m. ET NEW YORK and LONDON - 1 December 2020 (GLOBE NEWSWIRE) - Tiziana Life Sciences plc (NASDAQ: TLSA) (" Tiziana " or the " Company "), a
Life Sciences to Host Investor Update Call 2 December 2020 at 4:15 p.m. ET NEW YORK and LONDON - 1 December 2020 (GLOBE NEWSWIRE) - Tiziana Life Sciences plc (NASDAQ: TLSA) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology,
Read more →TLSATiziana Life Sciences PLC ("Tiziana" or the "Company") PDMR Dealing London, New York, 18 November 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (" Tiziana " or the " Company "), a biotechnology company focu
London, New York, 18 November 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified that
Read more →TLSATiziana Life Sciences PLC ("Tiziana" or "the Company") Phase 1b/2 Clinical Trial - Crohn's Disease Tiziana Life Sciences announces collaboration with Parexel Biotech to conduct phase 1b/2 clinical trial in patients with
Tiziana Life Sciences PLC ("Tiziana" or "the Company") Phase 1b/2 Clinical Trial - Crohn's Tiziana Life Sciences announces collaboration with Parexel Biotech to conduct phase 1b/2 clinical trial in patients with Crohn's Disease First Ever Study with take-home capsules of Fo
Read more →TLSATiziana Life Sciences announces collaboration with Parexel Biotech to conduct phase 1b/2 clinical trial in patients with Crohn’s Disease
First Ever Study with take-home capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody Potential to be a safer and effective alternative to the intravenous immunotherapies currently used for Crohn’s Disease Crohn’s Disease Therapeutics Market Size $4.7 Billion by 202
Read more →TLSATiziana Announces Initiation of Clinical Trial with Covid-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
Highly innovative first-in-class study for treating COVID-19 disease with nasally administered drug Trial facilitated with collaboration of Harvard Medical School and one of the world’s top Neurologist, Dr. Howard Weiner Patent for potentially revolutionary nasally administered
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Announces Initiation of Clinical Trial with Covid-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody - Hig
Initiation of Clinical Trial with Covid-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal November 2, 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovati
Read more →TLSATiziana Life Sciences PLC ("Tiziana" or "the Company") Exercise of options, Issue of Equity PDMR Dealing and Total Voting Rights London, New York, 29 October 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("
Tiziana Life Sciences PLC Exercise of options, Issue of Equity PDMR Dealing and Total Voting Rights London, New York, 29 October 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeuti
Read more →TLSATiziana Life Sciences PLC ("Tiziana" or the "Company") Demerger Update and timetable confirmation London, New York, 29 October 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (" Tiziana " or the " Company "),
Tiziana Life Sciences PLC ("Tiziana" or the "Company") Demerger Update and timetable confirmation London, New York, 29 October 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics
Read more →TLSATiziana Life Sciences Plc (" Tiziana " or the " Company ") Issue of Equity on Exercise of Warrants London, New York, 28 October 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (" Tiziana " or the " Company ")
of Equity on Exercise of Warrants New York, 28 October 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that
Read more →TLSATiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs) New York, London 27 October 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ( Tiziana or the Company ), a biotec
Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs) New York, London 27 October 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics fo
Read more →TLSATiziana Life Sciences Plc (" Tiziana " or the " Company ") Exercise of options, Issue of Equity PDMR Dealing and Total Voting Rights London, New York, 26 October 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS
Tiziana Life Sciences Plc ("Tiziana" or the "Company") Exercise of options, Issue of Equity PDMR Dealing and Total Voting Rights London, New York, 26 October 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company fo
Read more →TLSATiziana Life Sciences Plc ( Tiziana or the Company ) Issue of Equity on Exercise of Warrants London, New York, 22 October 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ( Tiziana or the Company ), a biotechn
Issue of Equity on Exercise of Warrants London, New York, 22 October 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today a
Read more →TLSATiziana Life Sciences Plc (" Tiziana " or the " Company ") Exercise of options, Issue of Equity PDMR Dealing and Total Voting Rights London, New York, 21 October 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS
of options, Issue of Equity PDMR Dealing and Total Voting Rights New York, 21 October 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious d
Read more →TLSATiziana Life Sciences Plc ( Tiziana or the Company ) Issue of Equity on Exercise of Warrants London, New York, 20 October 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ( Tiziana or the Company ), a biotechn
Tiziana Life Sciences Plc ("Tiziana" or the "Company") Issue of Equity on Exercise of Warrants London, New York, 20 October 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics fo
Read more →TLSATiziana Life Sciences Plc (the "Company") - Result of General Meeting
LONDON, Oct. 02, 2020 (GLOBE NEWSWIRE) -- At the General Meeting of the Company (Nasdaq: TLSA / AIM: TILS) held at 11.00 a.m. on 2 October 2020, both of the resolutions were duly passed. The anticipated timetable for the demerger of Accustem Sciences Limited (to be re-registered
Read more →TLSATHE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICT
INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014. FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LA
Read more →TLSATiziana Life Sciences plc ("Tiziana" or "the Company") Interim Results for the Six Months Ended 30 June 2020 Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unm
Results for the Six Months Ended 30 June 2020 pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need 30 September 2020 - Tiziana Life Sciences plc ("Tiziana", AIM: TILS, NASDAQ: TLSA), a biotechnology company that focuses o
Read more →TLSATiziana Life Sciences Interview to Air on Bloomberg International on The RedChip Money Report
LONDON and NEW YORK, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced an interview w
Read more →TLSATiziana Life Sciences Plc (" Tiziana " or the " Company ") Tiziana Life Sciences Interview to Air on Bloomberg International on the RedChip Money Report London, New York, 25 September 2020 - Tiziana Life Sciences plc (Na
Tiziana Life Sciences Plc ("Tiziana" or the "Company") Tiziana Life Sciences Interview to Air on Bloomberg International on the RedChip Money Report London, New York, 25 September 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a bio
Read more →TLSATiziana Life Sciences plc: Publication of Research Note
LONDON and NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), is pleased to note the publication of a new analyst research note from H C Wainwright & Co which is available on the Company’s website at htt
Read more →TLSATiziana Life Sciences Plc (" Tiziana " or the " Company ") Issue of Equity and Total Voting Rights London, New York, 21 September 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (" Tiziana " or the " Company
of Equity and Total Voting Rights New York, 21 September 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces tha
Read more →TLSAPublication of Research Note London, New York, 21 September 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (" Tiziana " or the " Company "), is pleased to note the publication of a new analyst research note
Publication of Research Note London, New York, 21 September 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), is pleased to note the publication of a new analyst research note from H C Wainwright & Co which is available on the Company's
Read more →TLSATiziana Life Sciences plc to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in Brazil
Nasal Administration of Foralumab is a potentially transformative approach for treating patients with Covid-19 NEW YORK and LONDON, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focu
Read more →TLSATiziana Life Sciences plc ( Tiziana or the Company ) Tiziana to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in Brazil Nasal
to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in Brazil Nasal Administration of Foralumab is a potentially transformative approach for treating patients with Covid-19. York/Londo
Read more →TLSATiziana Life Sciences Plc ("Tiziana" or the "Company") - Demerger of StemPrintER and Distribution in Specie
LONDON, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Plc (LSE: TILS, NASDAQ: TLSA) a biotechnology company focussed on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that, following a strategic review of its clinical trial
Read more →TLSATiziana Life Sciences Announces Planned Spin Out of StemPrintER into a New Publicly Listed Company, AccuStem Sciences Tiziana Shareholders to receive 1:1 share dividend in AccuStem Sciences NEW YORK/LONDON
Life Sciences Announces Planned Spin Out of StemPrintER into a New Publicly Listed Company, AccuStem Sciences Shareholders to receive 1:1 share dividend in AccuStem Sciences YORK/LONDON, September 16, 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Life Sciences Clarifies Reason for Filing an Amended ADS Registration Statement ADS Registration Statement filed in order to Increase Capacity under the ADS
Life Sciences Clarifies Reason for Filing an Amended ADS Registration Statement Registration Statement filed in order to Increase Capacity under the ADS Facility to Exchange Ordinary Shares for ADSs York/London, 28 August, 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM:
Read more →TLSATiziana Life Sciences Clarifies Reason for Filing an Amended ADS Registration Statement
NEW YORK and LONDON, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, today announced the clarifica
Read more →TLSATR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying
TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attac
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Exercise of Warrants and Issue of Equity and Total Voting Rights London, New York, 27 August 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" o
Tiziana Life Sciences plc ("Tiziana" or the "Company") Exercise of Warrants and Issue of Equity and Total Voting Rights London, New York, 27 August 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on i
Read more →TLSATiziana Life Sciences CEO Updates Shareholders on its Patent Portfolio, Clinical Pipeline, and Strategy in an Exclusive Interview
NEW YORK and LONDON, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, today announced that an inter
Read more →TLSATiziana Life Sciences PLC ("Tiziana" or the "Company") Grant of options - Director dealings London/New York, 26 August, 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) ("Tiziana" or the "Company"), a biotechno
26 August, 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that the board of directors of the Company (the "Board" o
Read more →TLSATiziana Granted a Patent on Methods and Use of Anti-IL-6/IL-6 receptor Monoclonal Antibodies as Prophylactic and Therapeutic Interventions for COVID-19 and other pulmonary diseases New York/London, 24 August, 2020 - Tizi
Tiziana Granted a Patent on Methods and Use of Anti-IL-6/IL-6 receptor Monoclonal Antibodies as Prophylactic and Therapeutic Interventions for COVID-19 and other pulmonary diseases New York/London, 24 August, 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) ("Tiziana
Read more →TLSATiziana Granted a Patent on the Use of Milciclib in Combination with Tyrosine Kinase Inhibitors for Treatment of Hepatocellular Carcinoma and other Cancers
NEW YORK and LONDON, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that the United States
Read more →TLSAThis announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. Tiziana Life Sciences plc (" Tiziana " or the " Company ") Tiziana Granted a Patent on the Use of Milciclib in Combin
announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. Granted a Patent on the Use of Milciclib in Combination with Tyrosine Kinase Inhibitors for Treatment of Hepatocellular Carcinoma York/London, 21 August, 2020 - Tiziana Life Scienc
Read more →TLSATiziana is Pleased to Retain Dr. Napoleone Ferrara to Serve on Its Scientific Advisory Board for an Additional Three-Year Term
- Dr. Ferrara is the discoverer of Avastin® and Lucentis®, multi-billion dollars antibody drugs from Genentech - A member of National Academy of Sciences and recipient of several prestigious awards, including the Lasker award. NEW YORK and LONDON, Aug. 20, 202
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Granted a Patent on Methods and Use of Anti-CD3 Monoclonal Antibodies for Treatment of Crohn's Disease New York/London, 18 August, 2020 - Tiziana Life Scienc
Tiziana Life Sciences plc Tiziana Granted a Patent on Methods and Use of Anti-CD3 Monoclonal Antibodies for Treatment of Crohn's Disease New York/London, 18 August, 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) ("Tiziana" or the "Company"), a biotechnology compan
Read more →TLSATiziana Granted a Patent on Methods and Use of Anti-CD3 Monoclonal Antibodies for Treatment of Crohn’s Disease
NEW YORK and LONDON, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that the United States
Read more →TLSATiziana Life Sciences to Present at BTIG's Virtual Biotechnology Conference NEW YORK and LONDON
Tiziana Life Sciences to Present at BTIG's Virtual Biotechnology Conference YORK and LONDON, August 11, 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a clinical stage biotechnology company developing targeted drugs for cancer, inflam
Read more →TLSATiziana Life Sciences plc Announces Closing of $57.25 Million Offering
LONDON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces the closing of its registere
Read more →TLSATiziana Life Sciences plc Tiziana Life Sciences plc Announces Closing of $57.25 Million Offering London, New York 5 August 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the Company or Tiziana ), a biotechn
of $57.25 Million Offering York 5 August 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces the closing of its
Read more →TLSATiziana Life Sciences Announces an Expedited Clinical Development Plan for Its Anti-Interleukin-6-Receptor, a Fully Human Monoclonal Antibody, for the Treatment of COVID-19 Patients
Recently signed agreements with four contract research organizations (“CROs”) to initiate GMP manufacturing, develop inhalation technology, conduct inhalation safety toxicity study in monkeys, and initiate a human clinical trial in COVID-19 patients This announcement contains in
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Life Sciences Announces an Expedited Clinical Development Plan for Its Anti-Interleukin-6-Receptor, a Fully Human Monoclonal Antibody, for the Treatment of C
Tiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Life Sciences Announces an Expedited Clinical Development Plan for Its Anti-Interleukin-6-Receptor, a Fully Human Monoclonal Antibody, for the Treatment of COVID-19 This announcement contains inside information f
Read more →TLSATHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO D
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUC
Read more →TLSATiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $57.25 million
NEW YORK and LONDON, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA; AIM: TILS) (the "Company" or "Tiziana"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced it has entered i
Read more →TLSATiziana Life Sciences plc: Tiziana Announces Submission of a Patent Application for Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients
NEW YORK and LONDON, July 31, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, is pleased to announce that it
Read more →TLSATiziana Life Sciences plc: Total Voting Rights
LONDON and NEW YORK, July 31, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immu
Read more →TLSATHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 Tiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Announces Submission of a Patent Application for N
ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 Announces Submission of a Patent Application for Nasal Administration of Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients York/London,
Read more →TLSATiziana Life Sciences plc ( Tiziana or the Company ) Total Voting Rights London, New York, 31 July 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the Company or Tiziana ), a US and UK biotechnology company
York, 31 July 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today updated its total
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Update on Timings and Corporate Actions New York/London, 30 July 2020 - Tiziana Life Sciences plc ("Tiziana", AIM: TILS, NASDAQ: TLSA) ("Tiziana" or the "Company"),
on Timings and Corporate Actions York/London, 30 July 2020 - Tiziana Life Sciences plc ("Tiziana", AIM: TILS, NASDAQ: TLSA) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, gives the fo
Read more →TLSATiziana Life Sciences plc ( Tiziana or the Company ) Early notification of proposed admission to the Official List and cancellation of trading on AIM Tiziana Life Sciences plc the dual listed (NASDAQ:TLSA & UK AIMS:TILS)
Tiziana Life Sciences plc notification of proposed admission to the Official List and cancellation of trading on AIM Life Sciences plc the dual listed (NASDAQ:TLSA & UK AIMS:TILS) today announces its intention to apply for admission to listing of its ordinary shares (the "Ordi
Read more →TLSATiziana Life Sciences to Participate in Investor Webinar to Provide Corporate Updates and Q&A Session on July 30, 2020
NEW YORK and LONDON, July 30, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced that Kunwar Sha
Read more →TLSATiziana Life Sciences plc: Early notification of proposed admission to the Official List and cancellation of trading on AIM
NEW YORK and LONDON, July 30, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc the dual listed (NASDAQ:TLSA & UK AIMS:TILS) today announces its intention to apply for admission to listing of its ordinary shares (the "Ordinary Shares") on the standard listing segment of the Offi
Read more →TLSATiziana Life Sciences plc ( Tiziana or the Company ) Exercise of Warrants and Issue of Equity and Total Voting Rights London, New York, 24 July 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or th
of Warrants and Issue of Equity and Total Voting Rights York, 24 July 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today a
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Director Appointment New York/London, 20 July 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a US and UK biotechnology company that focuses on the disc
York/London, 20 July 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, is pleased to announce the appointment of Mr.
Read more →TLSATiziana Announces Submission of Patent Application on Use of Foralumab, the Only Fully Human Anti-CD3 Monoclonal Antibody, to Enhance Success of CAR-T Therapy
NEW YORK and LONDON, July 16, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, is pleased to announce that it
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Announces Submission of Patent Application on Use of Foralumab, the Only Fully Human Anti-CD3 Monoclonal Antibody, to Enhance Success of CAR-T Therapy New Yo
Submission of Patent Application on Use of Foralumab, the Only Fully Human Anti-CD3 Monoclonal Antibody, to Enhance Success of July 16, 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therap
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Results of Annual General Meeting London, New York, 16 July 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK bio
of Annual General Meeting York, 16 July 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunolog
Read more →TLSATiziana Life Sciences plc Change to ADS Ratio - Updated
NEW YORK and LONDON, July 15, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc ("Tiziana", AIM: TILS, NASDAQ: TLSA), announces a ratio change to its sponsored Level 3 American Depositary Receipt ("ADR") programme. Please note that pursuant to the announcement earlier today, to
Read more →TLSATiziana Life Sciences plc Change to ADS Ratio
NEW YORK and LONDON, July 15, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc ("Tiziana", AIM: TILS, NASDAQ: TLSA), announces a ratio change to its sponsored Level 3 American Depositary Receipt ("ADR") programme. This corporate action, which is a 2.5 for 1 forward split for t
Read more →TLSATiziana Life Sciences plc ( Tiziana or the Company ) Tiziana Life Sciences Interview to Air on Bloomberg International on the RedChip Money Report NEW YORK and LONDON
Tiziana Life Sciences plc Tiziana Life Sciences Interview to Air on Bloomberg International on the RedChip Money Report NEW YORK and LONDON, July 10, 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a clinical stage biotechnology comp
Read more →TLSATiziana Life Sciences Interview to Air on Bloomberg International on the RedChip Money Report
NEW YORK and LONDON, July 10, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, today announced an interview
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Total Voting Rights and StemPrintER Demerger Update London, New York, 1 July 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana")
Voting Rights and StemPrintER Demerger Update York, 1 July 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in onc
Read more →TLSATiziana Life Sciences Announces Agreement with STC Biologics for GMP Manufacturing of an anti-Interleukin-6-Receptor Monoclonal Antibody for Clinical Studies in Patients with COVID-19
NEW YORK and LONDON, June 29, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, today announces the execution
Read more →TLSATiziana Life Sciences plc ( Tiziana or the Company ) Agreement with STC Biologics Tiziana Life Sciences Announces Agreement with STC Biologics for GMP Manufacturing of an anti-Interleukin-6-Receptor Monoclonal Antibody f
Life Sciences Announces Agreement with STC Biologics for GMP Manufacturing of an anti-Interleukin-6-Receptor Monoclonal Antibody for Clinical Studies in Patients with COVID-19. York/London - 29 June 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Annual General Meeting London, New York, 23 June 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology
York, 23 June 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that it
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Exercise of Warrants and Issue of Equity and Total Voting Rights London, New York, 22 June 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company"
Warrants and Issue of Equity and Total Voting Rights York, 22 June 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease
Read more →TLSATiziana Granted First-Ever Patent on a Transformational Technology for Oral Delivery of all Anti-CD3 Monoclonal Antibodies for Treatment of Human Diseases
First-ever granted patent on oral administration of anti-CD3 monoclonal antibodies for immunotherapies Transformational oral formulation technologies applicable to other antibodies This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Granted First-Ever Patent on a Transformational Technology for Oral Delivery of all Anti-CD3 Monoclonal Antibodies for Treatment of Human Diseases First-ever
Tiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Granted First-Ever Patent on a Transformational Technology for Oral Delivery of all Anti-CD3 Monoclonal Antibodies for Treatment of Human Diseases This announcement contains inside information for the purposes of
Read more →TLSATiziana Life Sciences PLC Directorate Change
LONDON and NEW YORK, June 18, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS) ("Tiziana" or the "Company"), the U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology an
Read more →TLSATiziana Life Sciences PLC ("Tiziana" or the "Company") Final Results for the Year Ended 31 December 2019 London / New York 18 June 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), (the "Company" or "Tiziana")
Results for the Year Ended 31 December 2019 / New York 18 June 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), (the "Company" or "Tiziana"), the U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human dise
Read more →TLSATiziana Life Sciences PLC ( Tiziana or the Company ) Directorate Change London / New York, 18 June 2020 - Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS), the U.S. and U.K. biotechnology company that focuses on the
Tiziana Life Sciences PLC ("Tiziana" or the "Company") London / New York, 18 June 2020 - Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS), the U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in on
Read more →TLSATiziana Life Sciences announces that its Scientific Advisory Board Chairman Dr. Howard Weiner received NIH grant to investigate Nasal Anti-CD3 for the treatment of Alzheimer’s disease
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, June 04, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focused on innovative therapeutics for onco
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Life Sciences announces that its Scientific Advisory Board Chairman Dr. Howard Weiner received NIH grant To investigate Nasal Anti-CD3 for the treatment of A
Sciences announces that its Scientific Advisory Board Chairman Dr. Howard Weiner received NIH grant To investigate Nasal Anti-CD3 for the treatment of Alzheimer's disease contains inside information for the purposes of Article 7 of EU Regulation 596/2014. 4 June 2020 - Tiziana
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Exercise of Warrants and Issue of Equity and Total Voting Rights London, New York, 2 June 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company"
of Warrants and Issue of Equity and Total Voting Rights York, 2 June 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disea
Read more →TLSATiziana Life Sciences plc ( Tiziana or the Company ) Correction - Exercise of Warrants and Issue of Equity and Total Voting Rights The announcement (RNS Number: 6069O) released on 2 June 2020 at 07:00 am stated that 1,49
- Exercise of Warrants and Issue of Equity and Total Voting Rights (RNS Number: 6069O) released on 2 June 2020 at 07:00 am stated that 1,498,685 new ordinary shares will be issued yielding 710,843 in cash proceeds, the announcement should have stated the number of shares to be
Read more →TLSAJune 2020 Tiziana Life Science plc Appointment of Broker Tiziana Life Sciences plc (AIM:TILS) is pleased to announce the appointment of Optiva Securities Limited as its broker with immediate effec
Life Sciences plc (AIM:TILS) is pleased to announce the appointment of Optiva Securities Limited as its broker with immediate Gabriele Cerrone, Chairman and founder +44 (0)20 7495 2379 Cairn Financial Advisers LLP (Nominated adviser) Liam Murray / Jo Turner + 44 (0)20 7213 0883
Read more →TLSATiziana Life Sciences announces presentation of StemPrintER, a superior prognostic test as compared to Oncotype DX to predict breast cancer
StemPrintER Outperforms Oncotype DX in analysis with 800+ samples from ER+/HER2- postmenopausal breast cancer patients SPARE Model is up to 40-50% more accurate than standard clinical markers in analysis with 1800+ samples for prediction of distant metastasis NEW YORK and LONDO
Read more →TLSATiziana Life Sciences plc (" Tiziana " or the " Company ") Tiziana Life Sciences Announces Intention to Demerge Its StemPrintER Genomics-Based Personalized Medicine Business as a Separate Listed Company New York and Lond
Life Sciences Announces Intention to Demerge Its StemPrintER Genomics-Based Personalized Medicine Business as a Separate Listed York and London, May 22, 2020 - Tiziana Life Sciences plc (NASDAQ: TLSA, AIM: TILS), a clinical stage biotechnology company developing targeted drugs
Read more →TLSATiziana Lifesciences Announces Intention to Demerge Its StemPrintER Genomics-Based Personalized Medicine Business as a Separate Listed Company
NEW YORK and LONDON, May 22, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, AIM: TILS), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, today announces that it intends to demerge its StemPrintER a
Read more →TLSATiziana Life Sciences plc (" Tiziana " or the " Company ") Tiziana Life Sciences Announces Online Publication of Two Abstracts at the American Society of Clinical Oncology (ASCO) Reporting Clinical Activity and Safety of
Sciences Announces Online Publication of Two Abstracts at the American Society of Clinical Oncology (ASCO) Reporting Clinical Activity and Safety of Milciclib in Patients with Advanced Hepatocellular Carcinoma This announcement contains inside information for the purposes of A
Read more →TLSATiziana Lifesciences Announces Online Publication of Two Abstracts at the American Society of Clinical Oncology (ASCO) Reporting Clinical Activity and Safety of Milciclib in Patients with Advanced Hepatocellular Carcinoma
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, May 14, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innov
Read more →TLSATiziana Life Sciences Announces Data Demonstrating StemPrintER’s Superiority Compared to Oncotype DX in Providing Prognostic Information to Conventional Clinical Parameters in Breast Cancer Patients in Poster Discussion Session at the American Society of Clinical Oncology (ASCO) Virtual Conference
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, May 14, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative thera
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Life Sciences to present two studies featuring StemPrintER, a stem cell biology-based Breast Cancer Prognostic Tool during the American Society of Clinical O
Life Sciences to present two studies featuring StemPrintER, a stem cell biology-based Breast Cancer Prognostic Tool during the American Society of Clinical Oncology (ASCO) Virtual Conference additional abstracts featuring Milciclib in treating Hepatocellular Carcinoma to be pub
Read more →TLSATiziana Life Sciences to present two studies featuring StemPrintER, a stem cell biology-based Breast Cancer Prognostic Tool during the American Society of Clinical Oncology (ASCO) Virtual Conference
NEW YORK and LONDON, May 11, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, announces that two abstracts on the Company’s stem cel
Read more →TLSATiziana Life Sciences plc ( Tiziana or the Company ) Tiziana Life Sciences Files Patent on Combination of Nanoparticle-Actinomycin D with Anti-Interleukin-6 Receptor Monoclonal Antibody for Treatment of Coronaviruses Com
Sciences Files Patent on Combination of Nanoparticle-Actinomycin D with Anti-Interleukin-6 Receptor Monoclonal Antibody for Treatment Combination of nanoparticle-Actinomycin D acting as an anti-viral treatment, with an anti-inflammatory agent may present a potential therapeutic
Read more →TLSATiziana Life Sciences Files Patent on Combination of Nanoparticle-Actinomycin D with Anti-Interleukin-6 Receptor Monoclonal Antibody for Treatment of Coronaviruses
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, April 27, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative the
Read more →TLSAApril 2020 Tiziana Life Sciences plc ( Tiziana or the Company ) Tiziana Life Sciences Acquires a Nanoparticle-Based Formulation Technology for Controlled Delivery of Actinomycin D for Treatment of Myelodysplastic syndrom
Tiziana Life Sciences Tiziana Life Sciences Acquires a Nanoparticle-Based Formulation Technology for Controlled Delivery of Actinomycin D for Treatment of Myelodysplastic syndrome and Acute Myeloid Leukemia Nanoparticle Actinomycin formulation minimizes toxicity and enhances
Read more →TLSATiziana Life Sciences Acquires a Nanoparticle-Based Formulation Technology for Controlled Delivery of Actinomycin D for Treatment of Myelodysplastic syndrome and Acute Myeloid Leukemia
Nanoparticle Actinomycin formulation minimizes toxicity and enhances tolerability by slow release of drug to control Cmax in blood This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, United Kingdom, April 2
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Issue of Equity and Resulting Total Voting Rights. Update on AIM cancellation and migration to Nasdaq. London, New York, 24 April 2020 - Tiziana Life Sciences plc (N
Tiziana Life Sciences plc of Equity and Resulting Total Voting Rights. Update on AIM cancellation and migration to Nasdaq. New York, 24 April 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuse
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Issue of Equity and Resulting Total Voting Rights This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. London / New
Tiziana Life Sciences plc ("Tiziana" or the "Company") Issue of Equity and Resulting Total Voting This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. London / New York 15 April 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA
Read more →TLSATiziana Lifesciences Develops Novel Investigational Treatment For Patients Infected with COVID-19 Utilizing Direct Delivery of Anti-Interlukin-6-Receptor Monoclonal Antibodies
NEW YORK and LONDON, April 09, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, announced today that it has developed investigationa
Read more →TLSATHE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 Tiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Life Sciences plc To Expedite De
THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 Tiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Life Sciences plc To Expedite Development of its Fully Human Anti-Interleukin-6-Recepto
Read more →TLSATiziana Life Science plc PDMR Dealing New York/London, 4 February 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics
Tiziana Life Science plc New York/London, 4 February 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that on the 3 Feb
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Life Sciences Announces F-3 Filing New York/London, 23 January 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing
Life Sciences Announces F-3 Filing York/London, 23 January 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces the Company
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Life Sciences Announces Appointment of Mr. Gregor MacRae to strengthen the Board New York/London, 21 January 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA /
Tiziana Life Sciences Announces Appointment of Mr. Gregor MacRae to strengthen the Board 21 January 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and onc
Read more →TLSATiziana Life Science Plc (the "Company") Proposed Cancellation from AIM New York/London, 13 January 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and devel
Tiziana Life Science Plc (the "Company") Proposed Cancellation from AIM York/London, 13 January 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncolo
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Reports Phase 1 Clinical Data Demonstrating Oral Treatment with Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, is Well-tolerated in Healthy Volunteer
Reports Phase 1 Clinical Data Demonstrating Oral Treatment with Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, is Well-tolerated in Healthy Volunteers announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. York/London, 9 Janua
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Announces Initiation of a Phase 1 Clinical Trial with Orally Administered Foralumab, a Fully Human anti-CD3 monoclonal antibody, in Healthy Volunteers This a
Tiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Announces Initiation of a Phase 1 Clinical Trial with Orally Administered Foralumab, a Fully Human anti-CD3 monoclonal antibody, in Healthy Volunteers This announcement contains inside information for the purpose
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Issue of equity and directorate change This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. New York/London, 20 Nov
Tiziana Life Sciences plc ("Tiziana" or the "Company") Issue of equity and directorate change This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. New York/London, 20 November 2019 - Tiziana Life Sciences plc (Nasdaq: TLSA /
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Issue of convertible unsecured loan notes with warrants attached to raise 1,434,000 This announcement contains inside information for the purposes of Article 7 of EU
Tiziana Life Sciences plc ("Tiziana" or the "Company") Issue of convertible unsecured loan notes with warrants attached to raise 1,434,000 This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. New York/London, 1 November 2019
Read more →TLSATiziana Life Sciences plc Change to ADS ratio London, 30 October 2019 - Tiziana Life Sciences plc ("Tiziana", AIM: TILS, NASDAQ: TLSA), announces a ratio change to its sponsored Level I American Depositary Receipt ("ADR"
2019 - Tiziana Life Sciences plc ("Tiziana", AIM: TILS, NASDAQ: TLSA), announces a ratio change to its sponsored Level I American Depositary Receipt ("ADR") programme. of ten (10) ordinary shares to one (1) American Depositary Share ("ADS") has been changed to five (5) ordinary
Read more →TLSA("Tiziana" or "the Company")
Tiziana Life Sciences plc ("Tiziana" or "the Company") Interim Results for the Six Months Ended Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need London, 30 September 2019 - Tiziana Life Sciences plc ("Ti
Read more →TLSATHE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATOR
INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN
Read more →TLSATiziana Life Sciences plc ("Tiziana Life Sciences" or the "Company") Tiziana Life Sciences Reports Positive Phase 2a Clinical Data Exhibiting Positive Clinical Activity with Milciclib Monotherapy in Advanced Sorafenib-re
Life Sciences" or the "Company") Life Sciences Reports Positive Phase 2a Clinical Data Exhibiting Positive Clinical Activity with Milciclib Monotherapy in Advanced Sorafenib-refractory or -intolerant Patients with Unresectable or Metastatic Hepatocellular Carcinoma York, 4 Sep
Read more →TLSATiziana Life Sciences plc Independent Third Party Article in New England Journal of Medicine reports on Intravenous Treatment with a Humanized Anti-CD3 mAb showing delays in progression of Type 1 Diabetes; Findings may h
Tiziana Life Sciences plc Party Article in New England Journal of Medicine reports on Intravenous Treatment with a Humanized Anti-CD3 mAb showing delays in progression of Type 1 Diabetes; Findings may have the potential to expand therapeutic benefits of Tiziana's Foralumab, th
Read more →TLSATiziana Life Sciences plc Newly Published Article Reporting Clinical Activity of Orally Administered OKT3, a Mouse Anti-CD3 Monoclonal Antibody, in Moderate to Severe Ulcerative Colitis Patients, Supports Tiziana's Oral
Published Article Reporting Clinical Activity of Orally Administered OKT3, a Mouse Anti-CD3 Monoclonal Antibody, in Moderate to Severe Ulcerative Colitis Patients, Supports Tiziana's Oral Monoclonal Antibody Platform party research conducted by leading U.S. institutions to be p
Read more →TLSATiziana Life Sciences plc (Incorporated in England and Wales with company number 09665181) PDMR dealings New York/London, 3 June 2019 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotec
Tiziana Life Sciences plc (Incorporated in England and Wales with company number 09665181) New York/London, 3 June 2019 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for in
Read more →TLSAMay 2019 Tiziana Life Sciences plc (the "Company") Results of Annual General Meeting Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS), a US and UK biotechnology company that focuses on the discovery and development o
Tiziana Life Sciences plc Results of Annual General Meeting Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology and immunology, today annou
Read more →TLSAMay 2019 Tiziana Life Sciences plc (the " Company ") Notice of Annual General Meeting Tiziana Life Sciences plc announces that its Annual General Meeting will be held at 10:00 a.m. on Friday 31 May 2019 at the offices of
Tiziana Life Sciences plc Notice of Annual General Meeting Tiziana Life Sciences plc announces that its Annual General Meeting will be held at 10:00 a.m. on Friday 31 May 2019 at the offices of Cooley (UK) LLP, Dashwood, 69 Old Broad Street, London EC2M 1QS. In connection wi
Read more →TLSATiziana Life Sciences plc (Incorporated in England and Wales with company number 09665181) PDMR dealings New York/London, 1 May 2019 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotech
Tiziana Life Sciences plc (Incorporated in England and Wales with company number 09665181) 1 May 2019 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and onco
Read more →TLSATiziana Life Sciences plc (Incorporated in England and Wales with company number 09665181) PDMR dealings New York/London, 25 April 2019 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biot
Tiziana Life Sciences plc (Incorporated in England and Wales with company number 09665181) New York/London, 25 April 2019 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for
Read more →TLSATiziana Life Sciences PLC ("Tiziana" or the "Company") Tiziana Reports Encouraging Interim Clinical Data from an Ongoing Phase 2a Trial with milciclib in Advanced Liver Cancer Patients - 80% of patients who completed tre
Tiziana Life Sciences PLC Encouraging Interim Clinical Data from an Ongoing Phase 2a Trial with milciclib in Advanced Liver Cancer Patients York/London, 24 April 2019 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and
Read more →TLSATiziana Life Sciences PLC ("Tiziana" or the "Company") Financial Results for the Year Ended 31 December 2018 London, 4 April 2019 - Tiziana Life Sciences plc (AIM: TILS), the clinical stage biotechnology company focused
Results for the Year Ended 31 December 2018 4 April 2019 - Tiziana Life Sciences plc (AIM: TILS), the clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, today announces its financial results for the year ended 31 Decembe
Read more →TLSATiziana Submits IND Application for Oral Formulation of Foralumab for Treatment of NASH
NEW YORK and LONDON, March 20, 2019 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (the "Company", "Tiziana Life Sciences" or "Tiziana") (NASDAQ: TLSA; AIM: TILS), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human dis
Read more →TLSATHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 Tiziana Life Sciences plc ("Tiziana" or the "Company") Directorate Change New York/London, 7 February 2019 - Tizi
ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 ("Tiziana" or the "Company") York/London, 7 February 2019 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and developmen
Read more →TLSATHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 Tiziana Life Sciences plc ("Tiziana" or the "Company") Exercise of Warrants & Issue of Equity New York/London, 11
THIS ANNOUNCEMENT CONTAINS INSIDE THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 Tiziana Life Sciences plc Exercise of Warrants & Issue of Equity December 2018 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Completes Patient Enrollment in a Phase 2a Trial to Evaluate Tolerability and Anti-Tumor Activity of Milciclib in Hepatocellular Carcinoma (HCC) New York/Lon
Tiziana Life Sciences plc ("Tiziana" or the "Company") Completes Patient Enrollment in a Phase 2a Trial to Evaluate Tolerability and Anti-Tumor Activity of Milciclib in Hepatocellular York/London, 3 December 2018 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotec
Read more →TLSATiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Announces Initiation of Phase 1 Clinical Trial with Nasal Administration of Foralumab, a Fully Human Anti-Cluster Definition 3 Monoclonal Antibody (anti-CD3
("Tiziana" or the "Company") Announces Initiation of Phase 1 Clinical Trial with Nasal Administration of Foralumab, a Fully Human Anti-Cluster Definition 3 Monoclonal Antibody (anti-CD3 mAb), in Healthy Volunteers breakthrough approach for treatment of neurodegenerative diseas
Read more →TLSATiziana Life Sciences PLC: Exercise of Warrants & Issue of Equity
LONDON, UNITED KINGDOM--(Marketwired - Mar 24, 2017) - Tiziana Life Sciences PLC (AIM: TILS) Tiziana Life Sciences PLC ("Tiziana" or the "Company") Exercise of Warrants & Issue of Equity London, 24 March 2017 - Tiziana Life Sciences plc (AIM: TILS, the "Company"), the clinica
Read more →TLSATiziana Life Sciences PLC Announces Interim Results for the Six Months Ended 30 June 2016
LONDON, UNTIED KINGDOM--(Marketwired - Sep 29, 2016) - Tiziana Life Sciences plc (AIM: TILS) Tiziana Life Sciences plc ("Tiziana" or "the Company") Interim Results for the Six Months Ended 30 June 2016 Advancing pipeline of next generation therapeutics and diagnostics for onc
Read more →TLSATiziana Life Sciences PLC: Confirmation of Capital Reduction
LONDON, UNITED KINGDOM--(Marketwired - Sep 15, 2016) - Tiziana Life Sciences plc (AIM: TILS) Tiziana Life Sciences PLC ("Tiziana" or the "Company") Confirmation of Capital Reduction London, 15 September 2016 - Tiziana Life Sciences plc (AIM: TILS), a clinical stage biotechnol
Read more →TLSATiziana Life Sciences PLC: Change of Registered Office
LONDON, UNITED KINGDOM--(Marketwired - Aug 18, 2016) - Tiziana Life Sciences plc (AIM: TILS) Tiziana Life Sciences PLC ("Tiziana" or the "Company") Change in Registered Office London, 18 August 2016 - Tiziana Life Sciences plc (AIM: TILS), a clinical stage biotechnology compa
Read more →TLSATiziana Life Sciences PLC: Result of AGM
LONDON, UNITED KINGDOM--(Marketwired - Jun 30, 2016) - Tiziana Life Sciences PLC (AIM: TILS) Tiziana Life Sciences PLC ("Tiziana" or the "Company") Result of Annual General Meeting ("AGM") and Issue of Equity London, 30 June 2016 - Tiziana Life Sciences plc (AIM: TILS), a cli
Read more →TLSATiziana Life Sciences PLC Announces Exercise of Warrants, Conversion of Convertible Loan Notes and Issue of Equity
LONDON, UNITED KINGDOM--(Marketwired - Jun 29, 2016) - Tiziana Life Sciences PLC (AIM: TILS) Tiziana Life Sciences PLC ("Tiziana" or the "Company") Exercise of Warrants, Conversion of Convertible Loan Notes and Issue of Equity London, 29 June 2016 - Tiziana Life Sciences plc
Read more →TLSATiziana Life Sciences PLC: Final Results for the year ended 31 December 2015
LONDON, UNITED KINGDOM--(Marketwired - Jun 7, 2016) - Tiziana Life Sciences PLC (AIM: TILS) Tiziana Life Sciences PLC ("Tiziana" or the "Company") Final Results for the year ended 31 December 2015 June 07, 2016 - Tiziana Life Sciences plc (AIM: TILS), a clinical stage biotech
Read more →TLSATiziana Life Sciences PLC: Appointment of Dr. Robert Evans
LONDON, UNITED KINGDOM--(Marketwired - May 4, 2016) - Tiziana Life Sciences PLC (AIM: TILS) Tiziana Life Sciences PLC ("Tiziana" or the "Company") Tiziana Life Sciences Expands its Clinical Team with Key Appointment of Dr. Robert Evans as Vice President of Clinical Sciences L
Read more →TLSATiziana Life Sciences PLC Announces Exercise of Warrants & Issue of Equity
LONDON, UNITED KINGDOM--(Marketwired - Apr 28, 2016) - Tiziana Life Sciences PLC (AIM: TILS) TIZIANA LIFE SCIENCES PLC Exercise of Warrants & Issue of Equity London, 28 April 2016 - Tiziana Life Sciences plc (AIM: TILS, the "Company"), the clinical stage biotechnology company
Read more →TLSATiziana Life Sciences plc Tiziano Lazzaretti Appointed as Chief Financial Officer
LONDON, UNITED KINGDOM--(Marketwired - Apr 4, 2016) - Tiziana Life Sciences plc (AIM: TILS) Tiziana Life Sciences plc ("Tiziana" or "the Company") Tiziano Lazzaretti appointed as Chief Financial Officer London, 4 April 2016 - Tiziana Life Sciences plc (AIM: TILS, the "Company
Read more →TLSATiziana Life Sciences PLC ("Tiziana" or the "Company") Fund Raising
LONDON, UNITED KINGDOM--(Marketwired - Jan 13, 2016) - Tiziana Life Sciences plc (AIM: TILS) (the "Company"), the clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, is pleased to announce that it has raised 709,406 (US$1,0
Read more →TLSATiziana Life Sciences PLC: Tiziana Life Sciences PLC Announces Development Plans for Foralumab & SAB Appointments
LONDON, UNITED KINGDOM--(Marketwired - Jan 11, 2016) - Tiziana Life Sciences plc (AIM: TILS) www.tizianalifesciences.com | AIM: TILS Tiziana Life Sciences PLC ("Tiziana" or the "Company") Tiziana announces plans for clinical development of foralumab, the company's fully human
Read more →Competitive Position
How TLSA ranks across every disease it competes inCompetitive Position is a premium feature
See how TLSA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial